Hot topics in allergen immunotherapy, 2023: Current status and future perspective
The importance of allergen immunotherapy (AIT) is multifaceted, encompassing both clinical and quality‐of‐life improvements and cost‐effectiveness in the long term. Key mechanisms of allergen tolerance induced by AIT include changes in memory type allergen‐specific T‐ and B‐cell responses towards a...
Uloženo v:
| Vydáno v: | Allergy (Copenhagen) Ročník 79; číslo 4; s. 823 - 842 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Denmark
Blackwell Publishing Ltd
01.04.2024
|
| Témata: | |
| ISSN: | 0105-4538, 1398-9995, 1398-9995 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | The importance of allergen immunotherapy (AIT) is multifaceted, encompassing both clinical and quality‐of‐life improvements and cost‐effectiveness in the long term. Key mechanisms of allergen tolerance induced by AIT include changes in memory type allergen‐specific T‐ and B‐cell responses towards a regulatory phenotype with decreased Type 2 responses, suppression of allergen‐specific IgE and increased IgG1 and IgG4, decreased mast cell and eosinophil numbers in allergic tissues and increased activation thresholds. The potential of novel patient enrolment strategies for AIT is taking into account recent advances in biomarkers discoveries, molecular allergy diagnostics and mobile health applications contributing to a personalized approach enhancement that can increase AIT efficacy and compliance. Artificial intelligence can help manage and interpret complex and heterogeneous data, including big data from omics and non‐omics research, potentially predict disease subtypes, identify biomarkers and monitor patient responses to AIT. Novel AIT preparations, such as synthetic compounds, innovative carrier systems and adjuvants, are also of great promise. Advances in clinical trial models, including adaptive, complex and hybrid designs as well as real‐world evidence, allow more flexibility and cost reduction. The analyses of AIT cost‐effectiveness show a clear long‐term advantage compared to pharmacotherapy. Important research questions, such as defining clinical endpoints, biomarkers of patient selection and efficacy, mechanisms and the modulation of the placebo effect and alternatives to conventional field trials, including allergen exposure chamber studies are still to be elucidated. This review demonstrates that AIT is still in its growth phase and shows immense development prospects. |
|---|---|
| AbstractList | The importance of allergen immunotherapy (AIT) is multifaceted, encompassing both clinical and quality‐of‐life improvements and cost‐effectiveness in the long term. Key mechanisms of allergen tolerance induced by AIT include changes in memory type allergen‐specific T‐ and B‐cell responses towards a regulatory phenotype with decreased Type 2 responses, suppression of allergen‐specific IgE and increased IgG1 and IgG4, decreased mast cell and eosinophil numbers in allergic tissues and increased activation thresholds. The potential of novel patient enrolment strategies for AIT is taking into account recent advances in biomarkers discoveries, molecular allergy diagnostics and mobile health applications contributing to a personalized approach enhancement that can increase AIT efficacy and compliance. Artificial intelligence can help manage and interpret complex and heterogeneous data, including big data from omics and non‐omics research, potentially predict disease subtypes, identify biomarkers and monitor patient responses to AIT. Novel AIT preparations, such as synthetic compounds, innovative carrier systems and adjuvants, are also of great promise. Advances in clinical trial models, including adaptive, complex and hybrid designs as well as real‐world evidence, allow more flexibility and cost reduction. The analyses of AIT cost‐effectiveness show a clear long‐term advantage compared to pharmacotherapy. Important research questions, such as defining clinical endpoints, biomarkers of patient selection and efficacy, mechanisms and the modulation of the placebo effect and alternatives to conventional field trials, including allergen exposure chamber studies are still to be elucidated. This review demonstrates that AIT is still in its growth phase and shows immense development prospects. The importance of allergen immunotherapy (AIT) is multifaceted, encompassing both clinical and quality‐of‐life improvements and cost‐effectiveness in the long term. Key mechanisms of allergen tolerance induced by AIT include changes in memory type allergen‐specific T‐ and B‐cell responses towards a regulatory phenotype with decreased Type 2 responses, suppression of allergen‐specific IgE and increased IgG₁ and IgG₄, decreased mast cell and eosinophil numbers in allergic tissues and increased activation thresholds. The potential of novel patient enrolment strategies for AIT is taking into account recent advances in biomarkers discoveries, molecular allergy diagnostics and mobile health applications contributing to a personalized approach enhancement that can increase AIT efficacy and compliance. Artificial intelligence can help manage and interpret complex and heterogeneous data, including big data from omics and non‐omics research, potentially predict disease subtypes, identify biomarkers and monitor patient responses to AIT. Novel AIT preparations, such as synthetic compounds, innovative carrier systems and adjuvants, are also of great promise. Advances in clinical trial models, including adaptive, complex and hybrid designs as well as real‐world evidence, allow more flexibility and cost reduction. The analyses of AIT cost‐effectiveness show a clear long‐term advantage compared to pharmacotherapy. Important research questions, such as defining clinical endpoints, biomarkers of patient selection and efficacy, mechanisms and the modulation of the placebo effect and alternatives to conventional field trials, including allergen exposure chamber studies are still to be elucidated. This review demonstrates that AIT is still in its growth phase and shows immense development prospects. The importance of allergen immunotherapy (AIT) is multifaceted, encompassing both clinical and quality-of-life improvements and cost-effectiveness in the long term. Key mechanisms of allergen tolerance induced by AIT include changes in memory type allergen-specific T- and B-cell responses towards a regulatory phenotype with decreased Type 2 responses, suppression of allergen-specific IgE and increased IgG1 and IgG4, decreased mast cell and eosinophil numbers in allergic tissues and increased activation thresholds. The potential of novel patient enrolment strategies for AIT is taking into account recent advances in biomarkers discoveries, molecular allergy diagnostics and mobile health applications contributing to a personalized approach enhancement that can increase AIT efficacy and compliance. Artificial intelligence can help manage and interpret complex and heterogeneous data, including big data from omics and non-omics research, potentially predict disease subtypes, identify biomarkers and monitor patient responses to AIT. Novel AIT preparations, such as synthetic compounds, innovative carrier systems and adjuvants, are also of great promise. Advances in clinical trial models, including adaptive, complex and hybrid designs as well as real-world evidence, allow more flexibility and cost reduction. The analyses of AIT cost-effectiveness show a clear long-term advantage compared to pharmacotherapy. Important research questions, such as defining clinical endpoints, biomarkers of patient selection and efficacy, mechanisms and the modulation of the placebo effect and alternatives to conventional field trials, including allergen exposure chamber studies are still to be elucidated. This review demonstrates that AIT is still in its growth phase and shows immense development prospects.The importance of allergen immunotherapy (AIT) is multifaceted, encompassing both clinical and quality-of-life improvements and cost-effectiveness in the long term. Key mechanisms of allergen tolerance induced by AIT include changes in memory type allergen-specific T- and B-cell responses towards a regulatory phenotype with decreased Type 2 responses, suppression of allergen-specific IgE and increased IgG1 and IgG4, decreased mast cell and eosinophil numbers in allergic tissues and increased activation thresholds. The potential of novel patient enrolment strategies for AIT is taking into account recent advances in biomarkers discoveries, molecular allergy diagnostics and mobile health applications contributing to a personalized approach enhancement that can increase AIT efficacy and compliance. Artificial intelligence can help manage and interpret complex and heterogeneous data, including big data from omics and non-omics research, potentially predict disease subtypes, identify biomarkers and monitor patient responses to AIT. Novel AIT preparations, such as synthetic compounds, innovative carrier systems and adjuvants, are also of great promise. Advances in clinical trial models, including adaptive, complex and hybrid designs as well as real-world evidence, allow more flexibility and cost reduction. The analyses of AIT cost-effectiveness show a clear long-term advantage compared to pharmacotherapy. Important research questions, such as defining clinical endpoints, biomarkers of patient selection and efficacy, mechanisms and the modulation of the placebo effect and alternatives to conventional field trials, including allergen exposure chamber studies are still to be elucidated. This review demonstrates that AIT is still in its growth phase and shows immense development prospects. The importance of allergen immunotherapy (AIT) is multifaceted, encompassing both clinical and quality-of-life improvements and cost-effectiveness in the long term. Key mechanisms of allergen tolerance induced by AIT include changes in memory type allergen-specific T- and B-cell responses towards a regulatory phenotype with decreased Type 2 responses, suppression of allergen-specific IgE and increased IgG and IgG , decreased mast cell and eosinophil numbers in allergic tissues and increased activation thresholds. The potential of novel patient enrolment strategies for AIT is taking into account recent advances in biomarkers discoveries, molecular allergy diagnostics and mobile health applications contributing to a personalized approach enhancement that can increase AIT efficacy and compliance. Artificial intelligence can help manage and interpret complex and heterogeneous data, including big data from omics and non-omics research, potentially predict disease subtypes, identify biomarkers and monitor patient responses to AIT. Novel AIT preparations, such as synthetic compounds, innovative carrier systems and adjuvants, are also of great promise. Advances in clinical trial models, including adaptive, complex and hybrid designs as well as real-world evidence, allow more flexibility and cost reduction. The analyses of AIT cost-effectiveness show a clear long-term advantage compared to pharmacotherapy. Important research questions, such as defining clinical endpoints, biomarkers of patient selection and efficacy, mechanisms and the modulation of the placebo effect and alternatives to conventional field trials, including allergen exposure chamber studies are still to be elucidated. This review demonstrates that AIT is still in its growth phase and shows immense development prospects. The importance of allergen immunotherapy (AIT) is multifaceted, encompassing both clinical and quality‐of‐life improvements and cost‐effectiveness in the long term. Key mechanisms of allergen tolerance induced by AIT include changes in memory type allergen‐specific T‐ and B‐cell responses towards a regulatory phenotype with decreased Type 2 responses, suppression of allergen‐specific IgE and increased IgG 1 and IgG 4 , decreased mast cell and eosinophil numbers in allergic tissues and increased activation thresholds. The potential of novel patient enrolment strategies for AIT is taking into account recent advances in biomarkers discoveries, molecular allergy diagnostics and mobile health applications contributing to a personalized approach enhancement that can increase AIT efficacy and compliance. Artificial intelligence can help manage and interpret complex and heterogeneous data, including big data from omics and non‐omics research, potentially predict disease subtypes, identify biomarkers and monitor patient responses to AIT. Novel AIT preparations, such as synthetic compounds, innovative carrier systems and adjuvants, are also of great promise. Advances in clinical trial models, including adaptive, complex and hybrid designs as well as real‐world evidence, allow more flexibility and cost reduction. The analyses of AIT cost‐effectiveness show a clear long‐term advantage compared to pharmacotherapy. Important research questions, such as defining clinical endpoints, biomarkers of patient selection and efficacy, mechanisms and the modulation of the placebo effect and alternatives to conventional field trials, including allergen exposure chamber studies are still to be elucidated. This review demonstrates that AIT is still in its growth phase and shows immense development prospects. |
| Author | Akdis, Cezmi A. Shamji, Mohamed H. Akdis, Mübeccel Jahnz‐Różyk, Karina Matricardi, Paolo M. Agache, Ioana Casale, Thomas B. Kosowska, Anna Pfaar, Oliver Jutel, Marek Zemelka‐Wiacek, Magdalena Dramburg, Stephanie |
| Author_xml | – sequence: 1 givenname: Magdalena orcidid: 0000-0001-7201-8638 surname: Zemelka‐Wiacek fullname: Zemelka‐Wiacek, Magdalena email: magdalena.zemelka‐wiacek@umw.edu.pl organization: Wroclaw Medical University – sequence: 2 givenname: Ioana orcidid: 0000-0001-7994-364X surname: Agache fullname: Agache, Ioana organization: Transylvania University – sequence: 3 givenname: Cezmi A. orcidid: 0000-0001-8020-019X surname: Akdis fullname: Akdis, Cezmi A. organization: University Zurich – sequence: 4 givenname: Mübeccel orcidid: 0000-0003-0554-9943 surname: Akdis fullname: Akdis, Mübeccel organization: University Zurich – sequence: 5 givenname: Thomas B. orcidid: 0000-0002-3149-7377 surname: Casale fullname: Casale, Thomas B. organization: University of South Florida – sequence: 6 givenname: Stephanie orcidid: 0000-0002-9303-3260 surname: Dramburg fullname: Dramburg, Stephanie organization: Charité Universitätsmedizin Berlin – sequence: 7 givenname: Karina orcidid: 0000-0002-3505-1858 surname: Jahnz‐Różyk fullname: Jahnz‐Różyk, Karina organization: Military Institute of Medicine‐National Research Institute – sequence: 8 givenname: Anna orcidid: 0000-0001-8991-0198 surname: Kosowska fullname: Kosowska, Anna organization: ALL‐MED Medical Research Institute – sequence: 9 givenname: Paolo M. orcidid: 0000-0001-5485-0324 surname: Matricardi fullname: Matricardi, Paolo M. organization: Charité Universitätsmedizin Berlin – sequence: 10 givenname: Oliver orcidid: 0000-0003-4374-9639 surname: Pfaar fullname: Pfaar, Oliver organization: University Hospital Marburg, Philipps‐Universität Marburg – sequence: 11 givenname: Mohamed H. orcidid: 0000-0003-3425-3463 surname: Shamji fullname: Shamji, Mohamed H. organization: National Heart and Lung Institute, Imperial College London – sequence: 12 givenname: Marek orcidid: 0000-0003-1555-9379 surname: Jutel fullname: Jutel, Marek email: marek.jutel@all‐med.wroclaw.pl organization: ALL‐MED Medical Research Institute |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37984449$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkc2KFDEUhYOMOD2tC19AAm4UrJn8VDrJ7IZGHaFBBF2H6tSNZqhKyvwo_fZGu2czKGaTzXe-5J57gc5CDIDQc0ouaTtXwzRdUqF78QitKNeq01qLM7QilIiuF1ydo4uc7wghkmnyBJ1zqVXf93qFPt3GgktcvM3YB9xMkL5CwH6ea4jlG6RhObzBjDB-jbc1JQgF5zKUmvEQRuxqqQnwAikvYIv_AU_RYzdMGZ6d7jX68u7t5-1tt_v4_sP2ZtfZXknRUbKXkmutRu2Io4oSDZopTbl1TBI5Ogl6T9pH9Ua4XuzBMUs2ko1yYzkFvkavjt4lxe8VcjGzzxamaQgQazacCi42Qkn-X7Q9y5ikSqqGvnyA3sWaQhvEcMII74lu3jV6caLqfobRLMnPQzqY-14bcHUEbIo5J3DG-laaj6GkwU-GEvN7c6b1bf5sriVeP0jcS__Gnuw__QSHf4PmZrc7Jn4BOPCkfA |
| CitedBy_id | crossref_primary_10_3390_jcm13237268 crossref_primary_10_2147_JAA_S541706 crossref_primary_10_1016_j_anai_2024_10_019 crossref_primary_10_3390_ijms25147602 crossref_primary_10_1111_all_16620 crossref_primary_10_1111_all_16423 crossref_primary_10_1111_all_16467 crossref_primary_10_1111_all_16248 crossref_primary_10_1007_s12016_025_09053_2 crossref_primary_10_1016_j_cca_2025_120533 crossref_primary_10_3389_fimmu_2024_1431351 crossref_primary_10_1111_cea_14482 crossref_primary_10_3390_ph17111510 crossref_primary_10_1111_imr_13392 crossref_primary_10_1007_s00210_025_04073_3 crossref_primary_10_1159_000536335 crossref_primary_10_1007_s11882_025_01199_5 crossref_primary_10_1111_all_16370 crossref_primary_10_3389_fimmu_2025_1613719 crossref_primary_10_1080_21645515_2025_2501358 crossref_primary_10_1002_clt2_12341 crossref_primary_10_1080_14712598_2025_2531035 crossref_primary_10_1016_j_allmed_2024_100010 crossref_primary_10_1111_all_16638 crossref_primary_10_1111_all_16518 crossref_primary_10_1016_j_jaci_2025_01_014 crossref_primary_10_3389_falgy_2025_1642315 crossref_primary_10_1055_a_2519_7180 |
| Cites_doi | 10.1172/JCI118963 10.1111/cea.12386 10.1185/030079906X112552 10.1002/jcp.29941 10.1111/pai.13829 10.1016/j.jaip.2020.11.046 10.1016/j.jaip.2022.11.036 10.1111/j.1398-9995.2010.02430.x 10.1016/j.jaci.2015.12.1300 10.1111/all.14723 10.1016/j.jaci.2020.03.029 10.1001/jama.2016.3964 10.1111/all.15089 10.1111/all.13598 10.1016/j.jaci.2017.06.014 10.1111/all.15217 10.1097/ACI.0000000000000808 10.1111/all.14639 10.1111/all.14773 10.1111/all.13805 10.1016/j.jaci.2013.01.014 10.1016/j.ebiom.2019.11.006 10.1371/journal.pone.0283141 10.1111/all.13749 10.1016/j.jaci.2022.01.012 10.1007/s40521-013-0006-5 10.1186/s13052-020-00870-z 10.1111/all.15550 10.1016/j.jaci.2022.10.007 10.1016/j.jaip.2021.11.017 10.1016/j.jaci.2012.02.026 10.1111/all.15485 10.1080/13696998.2019.1588737 10.1097/ACI.0000000000000857 10.3390/metabo11090613 10.1002/met.1905 10.1002/alr.23086 10.1056/NEJMra1510062 10.3389/fimmu.2021.720746 10.1016/j.waojou.2020.100487 10.1016/j.jaci.2013.01.049 10.1039/c7mo00051k 10.1016/j.jaci.2022.08.029 10.1038/s41467-018-03636-8 10.1111/pai.13517 10.1067/mai.2002.121317 10.1111/all.13317 10.1080/13645706.2019.1575882 10.1159/000233058 10.1067/mai.2003.1570 10.1111/all.14833 10.1111/all.14776 10.1111/all.13254 10.2147/JAA.S318892 10.1186/s13223-019-0344-3 10.1111/all.14969 10.1016/j.jaci.2021.06.012 10.1016/j.jaci.2013.03.019 10.1186/s12948-017-0058-3 10.15586/aei.v50i2.469 10.1007/s40629-021-00183-5 10.1056/NEJMoa1812856 10.1111/cea.13867 10.1002/sim.6472 10.1002/alr.23078 10.1016/0091-6749(82)90062-8 10.1038/s41746-021-00423-6 10.1111/pai.13569 10.1164/rccm.202209-1708OC 10.1002/eji.200322919 10.1007/s15007-021-4914-6 10.1016/j.immuni.2020.12.013 10.1111/all.15036 10.18176/jiaci.0060 10.1016/j.jaci.2022.01.011 10.1016/j.coi.2006.06.003 10.1016/j.jaip.2018.09.015 10.1007/s10198-018-0970-6 10.3389/fgene.2019.01381 10.1186/2045-7022-3-17 10.1172/JCI2250 10.1080/14737167.2020.1819793 10.1046/j.0019-2805.2001.01341.x 10.1016/j.jaip.2021.02.035 10.1186/s13601-020-00342-x 10.3111/13696998.2012.688904 10.1097/ACI.0000000000000757 10.1111/all.15778 10.1016/j.jaci.2021.12.260 10.1111/all.15199 10.1111/all.15321 10.1186/s13601-015-0071-x 10.1111/all.15107 10.3390/vaccines10101747 10.1016/s0091-6749(98)70079-x 10.3390/jpm12010066 10.1007/s11882-018-0827-1 10.1111/all.15117 10.1084/jem.20080193 10.1016/j.jaci.2014.09.049 10.2147/CEOR.S44079 10.1111/all.15408 10.1111/all.12383 10.1016/j.pharmthera.2022.108115 10.1097/ACI.0000000000000536 10.1111/all.15499 10.1111/all.13355 10.1111/all.14575 10.1002/clt2.12268 10.1111/all.13201 10.7554/eLife.64653 10.1016/j.jaci.2014.07.029 10.1016/j.jaci.2014.04.029 10.1186/s12913-023-09324-8 10.1111/all.15023 10.1111/all.14342 10.1111/all.13867 10.1080/03007995.2017.1359517 10.1111/all.13996 10.1111/j.1365-2222.2008.03191.x 10.1111/all.13429 10.1046/j.1365-2222.1997.d01-416.x 10.1016/j.jaci.2008.03.013 10.1016/j.jaci.2018.12.1018 10.1016/j.jaci.2011.10.045 10.1186/s13073-022-01102-1 10.1111/cea.12997 10.1016/j.jaci.2021.09.029 10.3310/hta17270 10.1016/S0140-6736(04)15592-X 10.1111/all.15667 10.1016/j.jaci.2009.02.030 10.1016/j.jaci.2009.11.022 10.1186/s12948-021-00150-z 10.1111/all.13953 10.1111/all.13135 10.1016/j.jaci.2020.10.029 10.1159/000443272 10.1016/j.alit.2022.05.010 10.1016/j.jaci.2018.06.041 10.1007/s00103-011-1427-6 10.1111/all.14264 10.4049/jimmunol.180.7.4514 10.1016/j.lanepe.2021.100275 10.1371/journal.pone.0011028 10.3390/jpm13050845 10.1111/all.14908 10.1016/j.jaci.2014.03.019 10.2217/imt-2022-0215 10.1111/j.1398-9995.2008.01774.x 10.12688/f1000research.13585.2 10.1111/all.14896 10.1016/j.jaci.2021.03.030 10.5415/apallergy.2022.12.e45 10.1111/all.14957 10.1111/imr.12555 10.1016/j.jaci.2017.02.044 10.1016/j.jaip.2014.01.010 10.1056/NEJMoa2212895 10.1016/j.jaci.2014.10.045 10.2500/aap.2020.41.200035 10.1016/j.jaci.2017.09.052 10.1056/NEJM199908123410702 10.1016/j.rmed.2023.107125 10.1038/nm1226 10.1007/s11882-023-01084-z 10.1111/all.13133 10.1111/j.1398-9995.2007.01451.x 10.1016/j.jaci.2014.01.042 10.1111/cea.13887 10.1183/13993003.00446-2022 10.3390/genes10030238 10.1097/ACI.0000000000000782 10.1016/j.jaci.2021.08.006 10.1080/13696998.2017.1419959 10.1111/all.15203 10.1111/all.15412 10.1016/j.jaci.2014.07.041 10.1177/1740774518755058 10.1016/j.jaci.2021.05.039 10.1111/all.15054 10.2196/16642 10.3389/fimmu.2021.590054 10.1111/all.14331 10.5414/ALX02343E 10.1111/2041-210X.13575 10.1111/pai.13433 10.1111/all.14817 10.1007/s00105-017-3937-0 10.1080/1744666X.2021.1886079 10.1111/all.13420 10.1111/pai.13854 10.1111/all.15252 10.1016/j.jaci.2020.08.005 10.1111/all.15327 10.1111/all.13338 10.1111/all.14710 10.1111/all.15529 10.1016/j.jaci.2018.10.028 10.1159/000531332 10.1159/000228032 10.1016/j.jaci.2014.06.024 10.5414/ALX02331E 10.1016/j.rmed.2021.106332 10.1111/all.14246 10.1080/21645515.2017.1348447 10.1126/science.1144603 10.1111/all.15506 10.2217/imt-2018-0087 10.1007/BF02802259 10.1016/j.jaci.2021.12.781 |
| ContentType | Journal Article |
| Copyright | 2023 The Authors. published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd. 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd. 2023. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2023 The Authors. published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd. – notice: 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd. – notice: 2023. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 H94 K9. 7X8 7S9 L.6 |
| DOI | 10.1111/all.15945 |
| DatabaseName | Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | AIDS and Cancer Research Abstracts AGRICOLA MEDLINE - Academic MEDLINE CrossRef |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1398-9995 |
| EndPage | 842 |
| ExternalDocumentID | 37984449 10_1111_all_15945 ALL15945 |
| Genre | reviewArticle Research Support, Non-U.S. Gov't Journal Article Review |
| GrantInformation_xml | – fundername: Ministry of Health funderid: SUBZ.A020.22.060 – fundername: Ministry of Health grantid: SUBZ.A020.22.060 |
| GroupedDBID | .3N .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 23M 24P 2WC 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8F7 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAKAS AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZCM ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHEFC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB AOETA ATUGU AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DC6 DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM E3Z EBS EJD EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D P6G PALCI PQQKQ Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ TEORI TR2 UB1 V9Y W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR XG1 Y6R ZGI ZXP ZZTAW ~IA ~KM ~WT AAMMB AAYXX AEFGJ AEYWJ AGHNM AGQPQ AGXDD AGYGG AIDQK AIDYY AIQQE CITATION O8X CGR CUY CVF ECM EIF NPM 7T5 H94 K9. 7X8 7S9 L.6 |
| ID | FETCH-LOGICAL-c4875-10b773998d9f0f18109e928913cf2707df7e9b0798965f45bef2c0672d76c31e3 |
| IEDL.DBID | 24P |
| ISICitedReferencesCount | 36 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001104383600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0105-4538 1398-9995 |
| IngestDate | Fri Jul 11 18:24:09 EDT 2025 Sun Nov 09 12:22:43 EST 2025 Fri Oct 03 11:11:29 EDT 2025 Mon Jul 21 05:58:53 EDT 2025 Sat Nov 29 04:10:45 EST 2025 Tue Nov 18 22:41:32 EST 2025 Wed Jan 22 16:13:05 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | allergen immunotherapy (AIT) efficacy endpoint novel vaccines trial design biomarkers |
| Language | English |
| License | Attribution-NonCommercial-NoDerivs 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4875-10b773998d9f0f18109e928913cf2707df7e9b0798965f45bef2c0672d76c31e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-3149-7377 0000-0002-3505-1858 0000-0001-8991-0198 0000-0003-4374-9639 0000-0003-1555-9379 0000-0001-7201-8638 0000-0003-0554-9943 0000-0001-5485-0324 0000-0001-7994-364X 0000-0002-9303-3260 0000-0001-8020-019X 0000-0003-3425-3463 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fall.15945 |
| PMID | 37984449 |
| PQID | 3020340915 |
| PQPubID | 34098 |
| PageCount | 20 |
| ParticipantIDs | proquest_miscellaneous_3153565873 proquest_miscellaneous_2892271878 proquest_journals_3020340915 pubmed_primary_37984449 crossref_citationtrail_10_1111_all_15945 crossref_primary_10_1111_all_15945 wiley_primary_10_1111_all_15945_ALL15945 |
| PublicationCentury | 2000 |
| PublicationDate | April 2024 |
| PublicationDateYYYYMMDD | 2024-04-01 |
| PublicationDate_xml | – month: 04 year: 2024 text: April 2024 |
| PublicationDecade | 2020 |
| PublicationPlace | Denmark |
| PublicationPlace_xml | – name: Denmark – name: Zurich |
| PublicationTitle | Allergy (Copenhagen) |
| PublicationTitleAlternate | Allergy |
| PublicationYear | 2024 |
| Publisher | Blackwell Publishing Ltd |
| Publisher_xml | – name: Blackwell Publishing Ltd |
| References | 2013; 3 2023; 78 2020; 20 2023; 184 2019; 10 2019; 15 2019; 19 2020; 13 2022; 22 2020; 10 2012; 15 2017; 278 2012; 129 2016; 35 2014; 134 2018; 7 2017; 72 1982; 68 2021; 76 2015; 135 2019; 22 2006; 22 2023; 210 2019; 28 1987 2009; 123 2016; 315 2007; 62 2022; 33 2010; 5 2019; 7 2020; 41 2021; 148 2021; 147 2017; 68 1953; 4 1999; 341 1997; 27 2020; 146 2023; 207 2008; 121 2017; 377 2018; 21 2021; 51 1996; 98 2022; 237 2014; 44 2003; 33 2018; 19 2018; 18 2021; 54 2007; 317 2023; 151 2022; 6 2022; 12 2020; 27 2022; 14 2022; 10 2020; 22 2018; 10 2016; 26 2005; 11 2018; 15 2018; 14 2018; 9(1) 2007; 39 2004; 363 2021; 21 2023; 34 2019; 50 2022; 71 2017; 47 2023; 7 2023; 388 1987; 5 2014; 69 2021; 30 2012; 55 2003; 111 2014; 1 2010; 65 2021; 32 2013; 17 2023; 23 2014; 2 2021; 236 2017; 33 2018; 379 2002; 105 2020; 46 2018; 73 2008; 63 2022; 77 2002; 109 2014; 6 2021; 9 2018; 142 2018; 141 2023; 13 2015; 5 2023; 11 2022; 150 1982; 70 2019; 74 2023; 18 2015; 168 2022; 50 2023; 15 2010; 125 2008 2006; 18 2007 2008; 205 2019; 143 2021; 14 2008; 180 2021; 13 2021; 10 2021; 12 2021; 11 2020; 75 2017; 15 2021; 178 2022; 60 2021; 17 2017; 13 2021; 19 2019 2018 2016 2016; 137 2013; 131 1998; 102 2022; 149 2009; 39 e_1_2_16_23_1 e_1_2_16_46_1 e_1_2_16_222_1 e_1_2_16_69_1 e_1_2_16_113_1 e_1_2_16_136_1 e_1_2_16_159_1 e_1_2_16_84_1 e_1_2_16_61_1 e_1_2_16_101_1 e_1_2_16_162_1 e_1_2_16_185_1 e_1_2_16_219_1 e_1_2_16_19_1 e_1_2_16_34_1 e_1_2_16_57_1 e_1_2_16_210_1 e_1_2_16_11_1 e_1_2_16_109_1 e_1_2_16_124_1 e_1_2_16_147_1 e_1_2_16_95_1 e_1_2_16_72_1 e_1_2_16_9_1 e_1_2_16_112_1 e_1_2_16_196_1 e_1_2_16_173_1 e_1_2_16_150_1 e_1_2_16_207_1 e_1_2_16_45_1 e_1_2_16_68_1 e_1_2_16_200_1 e_1_2_16_22_1 e_1_2_16_60_1 e_1_2_16_83_1 e_1_2_16_114_1 e_1_2_16_137_1 e_1_2_16_186_1 e_1_2_16_163_1 e_1_2_16_140_1 e_1_2_16_212_1 e_1_2_16_18_1 e_1_2_16_56_1 e_1_2_16_211_1 e_1_2_16_79_1 e_1_2_16_33_1 e_1_2_16_102_1 e_1_2_16_71_1 e_1_2_16_94_1 e_1_2_16_10_1 e_1_2_16_125_1 e_1_2_16_148_1 e_1_2_16_8_1 e_1_2_16_197_1 e_1_2_16_151_1 e_1_2_16_174_1 e_1_2_16_223_1 e_1_2_16_208_1 e_1_2_16_29_1 e_1_2_16_67_1 e_1_2_16_220_1 e_1_2_16_119_1 e_1_2_16_44_1 e_1_2_16_21_1 e_1_2_16_82_1 e_1_2_16_122_1 e_1_2_16_145_1 e_1_2_16_183_1 e_1_2_16_217_1 e_1_2_16_17_1 e_1_2_16_78_1 e_1_2_16_32_1 e_1_2_16_55_1 e_1_2_16_70_1 e_1_2_16_107_1 e_1_2_16_168_1 e_1_2_16_93_1 e_1_2_16_110_1 e_1_2_16_156_1 e_1_2_16_133_1 e_1_2_16_3_1 e_1_2_16_171_1 e_1_2_16_194_1 e_1_2_16_205_1 e_1_2_16_228_1 e_1_2_16_221_1 e_1_2_16_28_1 e_1_2_16_89_1 e_1_2_16_2_1 e_1_2_16_43_1 e_1_2_16_66_1 e_1_2_16_135_1 e_1_2_16_20_1 e_1_2_16_81_1 e_1_2_16_158_1 e_1_2_16_123_1 e_1_2_16_100_1 e_1_2_16_184_1 e_1_2_16_161_1 e_1_2_16_218_1 e_1_2_16_39_1 e_1_2_16_16_1 e_1_2_16_31_1 e_1_2_16_77_1 e_1_2_16_54_1 e_1_2_16_108_1 e_1_2_16_146_1 e_1_2_16_92_1 e_1_2_16_169_1 e_1_2_16_111_1 e_1_2_16_134_1 e_1_2_16_195_1 e_1_2_16_172_1 e_1_2_16_206_1 e_1_2_16_27_1 EMA (e_1_2_16_154_1) 2008 e_1_2_16_117_1 e_1_2_16_42_1 e_1_2_16_88_1 Drummond M (e_1_2_16_166_1) 1987 e_1_2_16_65_1 e_1_2_16_120_1 e_1_2_16_143_1 e_1_2_16_189_1 e_1_2_16_80_1 e_1_2_16_181_1 e_1_2_16_215_1 e_1_2_16_15_1 e_1_2_16_38_1 e_1_2_16_30_1 e_1_2_16_53_1 e_1_2_16_76_1 e_1_2_16_99_1 e_1_2_16_105_1 e_1_2_16_128_1 e_1_2_16_91_1 e_1_2_16_131_1 e_1_2_16_177_1 e_1_2_16_5_1 e_1_2_16_192_1 e_1_2_16_226_1 e_1_2_16_203_1 e_1_2_16_26_1 e_1_2_16_49_1 Incorvaia C (e_1_2_16_160_1) 2007; 39 e_1_2_16_41_1 e_1_2_16_64_1 e_1_2_16_87_1 e_1_2_16_118_1 e_1_2_16_179_1 e_1_2_16_121_1 e_1_2_16_167_1 e_1_2_16_144_1 e_1_2_16_182_1 e_1_2_16_216_1 e_1_2_16_14_1 e_1_2_16_37_1 e_1_2_16_98_1 e_1_2_16_52_1 e_1_2_16_129_1 e_1_2_16_75_1 e_1_2_16_106_1 e_1_2_16_90_1 e_1_2_16_132_1 e_1_2_16_155_1 e_1_2_16_178_1 e_1_2_16_4_1 e_1_2_16_193_1 e_1_2_16_170_1 e_1_2_16_204_1 e_1_2_16_227_1 e_1_2_16_25_1 e_1_2_16_48_1 e_1_2_16_63_1 e_1_2_16_86_1 e_1_2_16_115_1 e_1_2_16_138_1 e_1_2_16_40_1 e_1_2_16_164_1 e_1_2_16_187_1 e_1_2_16_141_1 e_1_2_16_213_1 e_1_2_16_13_1 e_1_2_16_36_1 e_1_2_16_59_1 e_1_2_16_74_1 e_1_2_16_103_1 e_1_2_16_97_1 e_1_2_16_51_1 e_1_2_16_126_1 e_1_2_16_149_1 e_1_2_16_7_1 e_1_2_16_209_1 e_1_2_16_198_1 e_1_2_16_175_1 e_1_2_16_152_1 e_1_2_16_201_1 e_1_2_16_190_1 e_1_2_16_224_1 Augustin M (e_1_2_16_157_1) 2018 e_1_2_16_24_1 e_1_2_16_47_1 e_1_2_16_139_1 e_1_2_16_85_1 e_1_2_16_62_1 e_1_2_16_116_1 e_1_2_16_142_1 e_1_2_16_188_1 e_1_2_16_165_1 e_1_2_16_214_1 e_1_2_16_180_1 e_1_2_16_12_1 e_1_2_16_35_1 e_1_2_16_58_1 e_1_2_16_104_1 e_1_2_16_96_1 e_1_2_16_73_1 e_1_2_16_50_1 e_1_2_16_127_1 e_1_2_16_199_1 e_1_2_16_153_1 e_1_2_16_176_1 e_1_2_16_6_1 e_1_2_16_130_1 e_1_2_16_202_1 e_1_2_16_225_1 e_1_2_16_191_1 |
| References_xml | – volume: 20 start-page: 437 issue: 5 year: 2020 end-page: 453 article-title: Burden and socioeconomics of asthma, allergic rhinitis, atopic dermatitis and food allergy publication-title: Expert Rev Pharmacoecon Outcomes Res – volume: 75 start-page: 2319 issue: 9 year: 2020 end-page: 2329 article-title: Cost‐effectiveness of grass pollen allergen immunotherapy in adults publication-title: Allergy – volume: 18 start-page: 71 issue: 12 year: 2018 article-title: Virus‐like particles as carrier systems to enhance immunomodulation in allergen immunotherapy publication-title: Curr Allergy Asthma Rep – volume: 68 start-page: 1 issue: 1 year: 1982 end-page: 6 article-title: Studies of allergen and allergoid preparations from purified timothy ( ) pollen extracts. I. Physicochemical characteristics and binding to allergen‐specific human IgE publication-title: Int Arch Allergy Appl Immunol – volume: 102 start-page: 157 issue: 2 year: 1998 end-page: 164 article-title: Immunologic changes associated with allergen immunotherapy publication-title: J Allergy Clin Immunol – volume: 18 start-page: 738 issue: 6 year: 2006 end-page: 744 article-title: Healthy immune response to allergens: T regulatory cells and more publication-title: Curr Opin Immunol – volume: 12 year: 2021 article-title: CpG adjuvant in allergen‐specific immunotherapy: finding the sweet spot for the induction of immune tolerance publication-title: Front Immunol – volume: 13 start-page: 255 issue: 3 year: 2023 end-page: 264 article-title: Systematic review of real‐world persistence and adherence in subcutaneous allergen immunotherapy publication-title: Int Forum Allergy Rhinol – volume: 76 start-page: 2229 issue: 7 year: 2021 end-page: 2233 article-title: Cost‐effectiveness of the subcutaneous house dust mite allergen immunotherapy plus pharmacotherapy for allergic asthma: a mathematical model publication-title: Allergy – volume: 22 issue: 3 year: 2020 article-title: Adherence to prescribed E‐diary recording by patients with seasonal allergic rhinitis: observational study publication-title: J Med Internet Res – volume: 76 start-page: 3659 issue: 12 year: 2021 end-page: 3686 article-title: Advances and highlights in biomarkers of allergic diseases publication-title: Allergy – volume: 10 start-page: 62 issue: 1 year: 2020 article-title: Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study publication-title: Clin Transl Allergy – volume: 134 start-page: 75 issue: 1 year: 2014 end-page: 81 article-title: Italian pediatric allergy network (I‐PAN). The effect of component‐resolved diagnosis on specific immunotherapy prescription in children with hay fever publication-title: J Allergy Clin Immunol – year: 2008 – volume: 149 start-page: 1373 issue: 4 year: 2022 end-page: 1382.e12 article-title: Allergen‐specific T cells and clinical features of food allergy: lessons from CoFAR immunotherapy cohorts publication-title: J Allergy Clin Immunol – volume: 30 start-page: 198 issue: 6 year: 2021 end-page: 206 article-title: Real world effectiveness and cost consequences of grass pollen SCIT compared with SLIT and symptomatic treatment publication-title: Allergo J Int – volume: 77 start-page: 3584 issue: 12 year: 2022 end-page: 3592 article-title: Real‐world evidence for the long‐term effect of allergen immunotherapy: current status on database‐derived European studies publication-title: Allergy – year: 2019 – volume: 15 start-page: 253 issue: 4 year: 2023 end-page: 266 article-title: Real‐world study: drug reduction in children with allergic rhinitis and asthma receiving immunotherapy publication-title: Immunotherapy – volume: 143 start-page: 2190 issue: 6 year: 2019 end-page: 2201.e9 article-title: Induction of human regulatory innate lymphoid cells from group 2 innate lymphoid cells by retinoic acid publication-title: J Allergy Clin Immunol – volume: 30 start-page: 39 year: 2021 article-title: Erratum zu: Die “Husteblume” der Techniker Krankenkasse: erste evaluierte App für Patienten mit allergischer Rhinokonjunktivitis und allergischem Asthma durch Pollen publication-title: Allergo J – volume: 22 start-page: 1203 issue: 6 year: 2006 end-page: 1210 article-title: Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective publication-title: Curr Med Res Opin – volume: 135 start-page: 913 issue: 4 year: 2015 end-page: 921.e9 article-title: Basophil expression of diamine oxidase: a novel biomarker of allergen immunotherapy response publication-title: J Allergy Clin Immunol – volume: 149 start-page: 212 issue: 1 year: 2022 end-page: 222.e9 article-title: Allergoid‐mannan conjugates reprogram monocytes into tolerogenic dendritic cells via epigenetic and metabolic rewiring publication-title: J Allergy Clin Immunol – volume: 77 start-page: 1835 issue: 6 year: 2022 end-page: 1842 article-title: A three‐stage design for allergen immunotherapy trials publication-title: Allergy – volume: 146 start-page: 1097 issue: 5 year: 2020 end-page: 1108 article-title: Molecular profiling of allergen‐specific antibody responses may enhance success of specific immunotherapy publication-title: J Allergy Clin Immunol – volume: 135 start-page: 636 issue: 3 year: 2015 end-page: 643 article-title: Environmental exposure chambers in allergen immunotherapy trials: current status and clinical validation needs publication-title: J Allergy Clin Immunol – volume: 73 start-page: 269 issue: 2 year: 2018 end-page: 283 article-title: Health economic analysis of allergen immunotherapy for the management of allergic rhinitis, asthma, food allergy and venom allergy: a systematic overview publication-title: Allergy – volume: 54 start-page: 291 issue: 2 year: 2021 end-page: 307.e7 article-title: Induction of IL‐10‐producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response publication-title: Immunity – volume: 77 start-page: 2147 issue: 7 year: 2022 end-page: 2162 article-title: Development and validation of combined symptom‐medication scores for allergic rhinitis publication-title: Allergy – volume: 68 start-page: 297 issue: 4 year: 2017 end-page: 306 article-title: Placeboeffekt in Studien zur allergenspezifischen Immuntherapie mit Inhalationsallergenen [Placebo effect in clinical trials with allergen‐specific immunotherapy with inhalant allergens] publication-title: Hautarzt – volume: 69 start-page: 854 issue: 7 year: 2014 end-page: 867 article-title: Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI position paper publication-title: Allergy – volume: 72 start-page: 1035 issue: 7 year: 2017 end-page: 1042 article-title: Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future – an EAACI position paper publication-title: Allergy – volume: 2 start-page: 156 issue: 2 year: 2014 end-page: 160 article-title: Allergy immunotherapy adherence and delivery route: location does not matter publication-title: J Allergy Clin Immunol Pract – volume: 13 issue: 7 year: 2023 article-title: Efficacy and safety of oral immunotherapy for peanut, cow's milk, and hen's egg allergy: a systematic review of randomized controlled trials publication-title: Clin Transl Allergy – year: 2007 – volume: 78 start-page: 550 issue: 2 year: 2023 end-page: 553 article-title: Prospective (e‐diary) vs retrospective (ARIA) measures of severity in allergic rhinoconjunctivitis: an observational compatibility study publication-title: Allergy – volume: 6 start-page: 187 year: 2014 end-page: 196 article-title: Economic evaluation of SQ‐standardized grass allergy immunotherapy tablet (Grazax(®)) in children publication-title: Clinicoecon Outcomes Res – volume: 27 year: 2020 article-title: A deep‐learning model to predict thunderstorms within 400 km South Texas domains publication-title: Meteorol Appl – volume: 32 start-page: 1287 issue: 6 year: 2021 end-page: 1295 article-title: Oral immunotherapy in severe cow's milk allergic patients treated with omalizumab: real life survey from a Spanish registry publication-title: Pediatr Allergy Immunol – volume: 184 start-page: 985 year: 2023 end-page: 993 article-title: Potential cost savings by switching from subcutaneous to intralymphatic insect venom immunotherapy publication-title: Int Arch Allergy Immunol – volume: 315 start-page: 1715 issue: 16 year: 2016 end-page: 1725 article-title: Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: a randomized clinical trial publication-title: JAMA – volume: 7 start-page: 111 year: 2018 article-title: Real world evidence (RWE) – a disruptive innovation or the quiet evolution of medical evidence generation? publication-title: F1000Res – volume: 78 start-page: 1020 issue: 4 year: 2023 end-page: 1035 article-title: High‐dimensional immune profiles correlate with phenotypes of peanut allergy during food‐allergic reactions publication-title: Allergy – volume: 134 start-page: 1193 issue: 5 year: 2014 end-page: 1195.e4 article-title: Seasonal increases in peripheral innate lymphoid type 2 cells are inhibited by subcutaneous grass pollen immunotherapy publication-title: J Allergy Clin Immunol – volume: 147 start-page: 1507 issue: 4 year: 2021 end-page: 1510.e8 article-title: IL‐10‐producing innate lymphoid cells increased in patients with house dust mite allergic rhinitis following immunotherapy publication-title: J Allergy Clin Immunol – volume: 32 start-page: 776 issue: 4 year: 2021 end-page: 778 article-title: Machine learning approach and oral food challenge with heated egg publication-title: Pediatr Allergy Immunol – volume: 129 start-page: 1290 issue: 5 year: 2012 end-page: 1296 article-title: Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections publication-title: J Allergy Clin Immunol – volume: 388 start-page: 1755 issue: 19 year: 2023 end-page: 1766 article-title: Phase 3 trial of Epicutaneous immunotherapy in toddlers with Peanut allergy publication-title: N Engl J Med – volume: 9 start-page: 1864 issue: 5 year: 2021 end-page: 1870 article-title: Serum Periostin as a biomarker for predicting clinical response to house dust mite sublingual immunotherapy in allergic rhinitis publication-title: J Allergy Clin Immunol Pract – volume: 76 start-page: 629 issue: 3 year: 2021 end-page: 647 article-title: Placebo effects in allergen immunotherapy‐an EAACI task force position paper publication-title: Allergy – volume: 76 start-page: 2555 issue: 8 year: 2021 end-page: 2564 article-title: IgE‐cross‐blocking antibodies to Fagales following sublingual immunotherapy with recombinant bet v 1 publication-title: Allergy – volume: 41 start-page: 271 issue: 4 year: 2020 end-page: 277 article-title: Long‐term efficacy of injected allergen immunotherapy for treatment of grass pollen allergy in elderly patients with allergic rhinitis publication-title: Allergy Asthma Proc – volume: 62 start-page: 943 issue: 8 year: 2007 end-page: 948 article-title: Specific immunotherapy has long‐term preventive effect of seasonal and perennial asthma: 10‐year follow‐up on the PAT study publication-title: Allergy – volume: 1 start-page: 91 issue: 1 year: 2014 end-page: 106 article-title: Allergen peptides, recombinant allergens and Hypoallergens for allergen‐specific immunotherapy publication-title: Curr Treat Options Allergy – volume: 363 start-page: 608 issue: 9409 year: 2004 end-page: 615 article-title: Relation of CD4+CD25+ regulatory T‐cell suppression of allergen‐driven T‐cell activation to atopic status and expression of allergic disease publication-title: Lancet – volume: 32 start-page: 1654 issue: 8 year: 2021 end-page: 1662 article-title: Metabolomics reveals a correlation between hydroxyeicosatetraenoic acids and allergic asthma: evidence from three years' immunotherapy publication-title: Pediatr Allergy Immunol – volume: 237 year: 2022 article-title: Allergen immunotherapy for allergic airway diseases: use lessons from the past to design a brighter future publication-title: Pharmacol Ther – volume: 22 start-page: 132 issue: 2 year: 2022 end-page: 136 article-title: Update on the use of allergen challenge chambers in immunotherapy: clinical implications publication-title: Curr Opin Allergy Clin Immunol – volume: 151 start-page: 192 issue: 1 year: 2023 end-page: 201 article-title: Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: a randomized controlled trial publication-title: J Allergy Clin Immunol – volume: 76 start-page: 2827 issue: 9 year: 2021 end-page: 2839 article-title: An exhausted phenotype of TH 2 cells is primed by allergen exposure, but not reinforced by allergen‐specific immunotherapy publication-title: Allergy – volume: 149 start-page: 881 issue: 3 year: 2022 end-page: 883 article-title: Real‐world evidence: methods for assessing long‐term health and effectiveness of allergy immunotherapy publication-title: J Allergy Clin Immunol – volume: 11 start-page: S69 issue: 4 Suppl year: 2005 end-page: S76 article-title: Peptide‐based therapeutic vaccines for allergic and autoimmune diseases publication-title: Nat Med – volume: 77 start-page: 1873 issue: 6 year: 2022 end-page: 1884 article-title: Phase 2, randomized multi oral immunotherapy with omalizumab ‘real life’ study publication-title: Allergy – volume: 149 start-page: 189 issue: 1 year: 2022 end-page: 199 article-title: Novel antibody cocktail targeting bet v 1 rapidly and sustainably treats birch allergy symptoms in a phase 1 study publication-title: J Allergy Clin Immunol – volume: 19 start-page: 10 issue: 1 year: 2021 article-title: Personalized medicine and allergen immunotherapy: the beginning of a new era? publication-title: Clin Mol Allergy – volume: 76 start-page: 3374 issue: 11 year: 2021 end-page: 3382 article-title: Advances in allergen‐specific immune cell measurements for improved detection of allergic sensitization and immunotherapy responses publication-title: Allergy – volume: 78 start-page: 2085 year: 2023 end-page: 2088 article-title: The artificial intelligence (AI) revolution: how important for scientific work and its reliable sharing publication-title: Allergy – volume: 12 issue: 4 year: 2022 article-title: Mechanisms and biomarkers of successful allergen‐specific immunotherapy publication-title: Asia Pac Allergy – volume: 6 start-page: 167 year: 2022 end-page: 232 article-title: Guideline on allergen immunotherapy in IgE‐mediated allergic diseases: S2K guideline of the German Society of Allergology and Clinical Immunology (DGAKI), Society of Pediatric Allergology and Environmental Medicine (GPA), medical Association of German Allergologists (AeDA), Austrian Society of Allergology and Immunology (ÖGAI), Swiss Society for Allergology and Immunology (SSAI), German dermatological society (DDG), German Society of Oto‐Rhino‐Laryngology, head and neck surgery (DGHNO‐KHC), German Society of Pediatrics and Adolescent Medicine (DGKJ), Society of Pediatric Pulmonology (GPP), German respiratory society (DGP), German professional Association of Otolaryngologists (BVHNO), German Association of Paediatric and Adolescent Care Specialists (BVKJ), Federal Association of Pneumologists, sleep and respiratory physicians (BdP), professional Association of German Dermatologists (BVDD) publication-title: Allergol Select – volume: 17 start-page: 255 issue: 3 year: 2021 end-page: 268 article-title: Pharmacoeconomics of allergy immunotherapy versus pharmacotherapy publication-title: Expert Rev Clin Immunol – volume: 141 start-page: 293 issue: 1 year: 2018 end-page: 299.e6 article-title: Fusion proteins of flagellin and the major birch pollen allergen bet v 1 show enhanced immunogenicity, reduced allergenicity, and intrinsic adjuvanticity publication-title: J Allergy Clin Immunol – volume: 46 start-page: 105 issue: 1 year: 2020 article-title: Digital technologies for an improved management of respiratory allergic diseases: 10 years of clinical studies using an online platform for patients and physicians publication-title: Ital J Pediatr – volume: 51 start-page: 821 issue: 6 year: 2021 end-page: 828 article-title: @IT2020: an innovative algorithm for allergen immunotherapy prescription in seasonal allergic rhinitis publication-title: Clin Exp Allergy – volume: 76 start-page: 456 issue: 2 year: 2021 end-page: 470 article-title: Roles of follicular helper and regulatory T cells in allergic diseases and allergen immunotherapy publication-title: Allergy – volume: 77 start-page: 1667 issue: 6 year: 2022 end-page: 1684 article-title: EAACI position paper on the clinical use of the bronchial allergen challenge: unmet needs and research priorities publication-title: Allergy – volume: 74 start-page: 594 issue: 3 year: 2019 end-page: 604 article-title: Real‐world benefits of allergen immunotherapy for birch pollen‐associated allergic rhinitis and asthma publication-title: Allergy – volume: 50 start-page: 421 year: 2019 end-page: 432 article-title: Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen‐specific IgG4 response publication-title: EBioMedicine – volume: 76 start-page: 2002 issue: 7 year: 2021 end-page: 2016 article-title: Innate lymphoid cells: the missing part of a puzzle in food allergy publication-title: Allergy – volume: 76 start-page: 1907 issue: 6 year: 2021 end-page: 1911 article-title: Immunological changes in peripheral blood following nasal allergen challenge in subjects with allergic rhinitis pre‐ and post‐peptide immunotherapy: an open‐label clinical study publication-title: Allergy – volume: 65 start-page: 1558 issue: 12 year: 2010 end-page: 1565 article-title: Early markers for protective mechanisms during rush venom immunotherapy publication-title: Allergy – volume: 18 issue: 4 year: 2023 article-title: Food anaphylaxis diagnostic marker compilation in machine learning design and validation publication-title: PLoS ONE – volume: 72 start-page: 1022 issue: 7 year: 2017 end-page: 1034 article-title: Novel approaches and perspectives in allergen immunotherapy publication-title: Allergy – volume: 15 start-page: 27 year: 2019 article-title: Sublingual immunotherapy tablet for the treatment of house dust mite allergic rhinitis in Canada: an alternative to minimize treatment costs? publication-title: Allergy Asthma Clin Immunol – volume: 3 issue: 1 year: 2013 article-title: Novel birch pollen specific immunotherapy formulation based on contiguous overlapping peptides publication-title: Clin Transl Allergy – volume: 135 start-page: 771 issue: 3 year: 2015 end-page: 780.e8 article-title: IL‐10‐overexpressing B cells regulate innate and adaptive immune responses publication-title: J Allergy Clin Immunol – volume: 123 start-page: 735 issue: 4 year: 2009 end-page: 746 article-title: Mechanisms and treatment of allergic disease in the big picture of regulatory T cells publication-title: J Allergy Clin Immunol – volume: 44 start-page: 1246 issue: 10 year: 2014 end-page: 1254 article-title: The impact of telemonitoring on adherence to nasal corticosteroid treatment in children with seasonal allergic rhinoconjunctivitis publication-title: Clin Exp Allergy – volume: 78 start-page: 168 issue: 1 year: 2023 end-page: 177 article-title: Validated allergen exposure chamber is plausible tool for the assessment of house dust mite‐triggered allergic rhinitis publication-title: Allergy – volume: 77 start-page: 2313 issue: 8 year: 2022 end-page: 2336 article-title: COVID‐19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals‐EAACI recommendations publication-title: Allergy – volume: 76 start-page: 1041 issue: 4 year: 2021 end-page: 1052 article-title: Personalized medicine for allergy treatment: allergen immunotherapy still a unique and unmatched model publication-title: Allergy – volume: 13 year: 2021 article-title: Long‐term real‐world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma: results from the REACT study, a retrospective cohort study publication-title: Lancet Reg Health Eur – volume: 55 start-page: 303 issue: 3 year: 2012 end-page: 307 article-title: Prävalenz und sozioökonomische Bedeutung von Allergien in Deutschland [Prevalence and socio‐economic relevance of allergies in Germany] publication-title: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz – volume: 9(1) start-page: 1421 year: 2018 article-title: Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement publication-title: Nat Commun – volume: 142 start-page: 497 issue: 2 year: 2018 end-page: 509.e9 article-title: Safety and efficacy of immunotherapy with the recombinant B‐cell epitope‐based grass pollen vaccine BM32 publication-title: J Allergy Clin Immunol – volume: 35 start-page: 325 issue: 3 year: 2016 end-page: 347 article-title: Twenty‐five years of confirmatory adaptive designs: opportunities and pitfalls publication-title: Stat Med – volume: 77 start-page: 2888 issue: 10 year: 2022 end-page: 2908 article-title: Omics technologies in allergy and asthma research: an EAACI position paper publication-title: Allergy – volume: 76 start-page: 1528 issue: 5 year: 2021 end-page: 1538 article-title: Basophil sensitivity reflects long‐term clinical outcome of subcutaneous immunotherapy in grass pollen‐allergic patients publication-title: Allergy – volume: 5 issue: 6 year: 2010 article-title: Tracking antigen‐specific T‐cells during clinical tolerance induction in humans publication-title: PLoS ONE – volume: 236 start-page: 863 issue: 2 year: 2021 end-page: 876 article-title: New and old adjuvants in allergen‐specific immunotherapy: with a focus on nanoparticles publication-title: J Cell Physiol – volume: 14 start-page: 1045 year: 2021 end-page: 1063 article-title: Short‐term subcutaneous allergy immunotherapy and dupilumab are well tolerated in allergic rhinitis: a randomized trial publication-title: J Asthma Allergy – volume: 11 start-page: 1134 issue: 4 year: 2023 end-page: 1146 article-title: Omalizumab in IgE‐mediated food allergy: A systematic review and meta‐analysis publication-title: J Allergy Clin Immunol Pract – volume: 33 issue: 7 year: 2022 article-title: Der p 23‐specific IgE response throughout childhood and its association with allergic disease: a birth cohort study publication-title: Pediatr Allergy Immunol – volume: 78 start-page: 1742 year: 2023 end-page: 1757 article-title: EAACI guidelines on environmental science in allergic diseases and asthma – leveraging artificial intelligence and machine learning to develop a causality model in exposomics publication-title: Allergy – volume: 10 start-page: 1149 issue: 13 year: 2018 end-page: 1161 article-title: Efficacy and tolerability of a house dust mite allergoid in allergic bronchial asthma: a randomized dose‐ranging trial publication-title: Immunotherapy – volume: 131 start-page: 1342 issue: 5 year: 2013 end-page: 1349.e6 article-title: Randomized controlled trial of a ragweed allergy immunotherapy tablet in north American and European adults publication-title: J Allergy Clin Immunol – volume: 63 start-page: 1455 issue: 11 year: 2008 end-page: 1463 article-title: Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and toll‐like receptors publication-title: Allergy – volume: 102 start-page: 98 issue: 1 year: 1998 end-page: 106 article-title: Role of interleukin 10 in specific immunotherapy publication-title: J Clin Invest – volume: 148 start-page: 1061 issue: 4 year: 2021 end-page: 1071.e11 article-title: Differential induction of allergen‐specific IgA responses following timothy grass subcutaneous and sublingual immunotherapy publication-title: J Allergy Clin Immunol – volume: 33 start-page: 2039 issue: 11 year: 2017 end-page: 2047 article-title: Healthcare costs for allergic rhinitis patients on allergy immunotherapy: a retrospective observational study publication-title: Curr Med Res Opin – volume: 73 start-page: 5 issue: Suppl 104 year: 2018 end-page: 23 article-title: Perspectives in allergen immunotherapy: 2017 and beyond publication-title: Allergy – volume: 47 start-page: 1631 issue: 12 year: 2017 end-page: 1639 article-title: Overcoming severe adverse reactions to venom immunotherapy using anti‐IgE antibodies in combination with a high maintenance dose publication-title: Clin Exp Allergy – volume: 14 start-page: 101 issue: 1 year: 2022 article-title: Clinical trial design in the era of precision medicine publication-title: Genome Med – volume: 7 start-page: 47 year: 2023 end-page: 56 article-title: Real‐life evidence in allergen immunotherapy: moving forward with mHealth apps publication-title: Allergol Select – volume: 51 start-page: 985 issue: 8 year: 2021 end-page: 988 article-title: BSACI registry for immunotherapy (BRIT): providing safe and effective immunotherapy for allergies and urticaria publication-title: Clin Exp Allergy – volume: 146 start-page: 1080 issue: 5 year: 2020 end-page: 1088 article-title: Early epitope‐specific IgE antibodies are predictive of childhood peanut allergy publication-title: J Allergy Clin Immunol – volume: 137 start-page: 358 issue: 2 year: 2016 end-page: 368 article-title: International consensus on allergen immunotherapy II: mechanisms, standardization, and pharmacoeconomics publication-title: J Allergy Clin Immunol – volume: 75 start-page: 259 issue: 2 year: 2020 end-page: 272 article-title: The role of mobile health technologies in allergy care: an EAACI position paper publication-title: Allergy – volume: 21 start-page: 576 issue: 6 year: 2021 end-page: 582 article-title: Nanoparticles in allergen immunotherapy publication-title: Curr Opin Allergy Clin Immunol – volume: 98 start-page: 1676 issue: 7 year: 1996 end-page: 1683 article-title: Epitope‐specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL‐2 and IL‐15 in vitro publication-title: J Clin Invest – volume: 34 issue: Suppl 28 year: 2023 article-title: EAACI molecular allergology User's guide 2.0 publication-title: Pediatr Allergy Immunol – volume: 39 start-page: 562 issue: 4 year: 2009 end-page: 570 article-title: Use of A‐type CpG oligodeoxynucleotides as an adjuvant in allergen‐specific immunotherapy in humans: a phase I/IIa clinical trial publication-title: Clin Exp Allergy – volume: 50 start-page: 1 issue: 2 year: 2022 end-page: 6 article-title: Combination therapy of specific aeroallergens immunotherapy and omalizumab, in children with severe asthma publication-title: Allergol Immunopathol (Madr) – volume: 33 start-page: 1205 issue: 5 year: 2003 end-page: 1214 article-title: IL‐10 and TGF‐beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy publication-title: Eur J Immunol – volume: 14 start-page: 8 issue: 1 year: 2018 end-page: 25 article-title: Data integration and predictive modeling methods for multi‐omics datasets publication-title: Mol Omics – volume: 10 start-page: 1864 issue: 7 year: 2022 end-page: 1873.e10 article-title: Safety of Epicutaneous immunotherapy in Peanut‐allergic children: REALISE randomized clinical trial results publication-title: J Allergy Clin Immunol Pract – volume: 129 start-page: 834 issue: 3 year: 2012 end-page: 839.e8 article-title: Molecular profiles of IgE to Phleum pratense in children with grass pollen allergy: implications for specific immunotherapy publication-title: J Allergy Clin Immunol – volume: 21 start-page: 361 issue: 4 year: 2021 end-page: 367 article-title: Real‐life studies in allergen immunotherapy publication-title: Curr Opin Allergy Clin Immunol – volume: 7 start-page: 451 issue: 2 year: 2019 end-page: 461.e7 article-title: Long‐term outcome of Peanut Oral immunotherapy facilitated initially by omalizumab publication-title: J Allergy Clin Immunol Pract – volume: 9 start-page: 1805 issue: 5 year: 2021 end-page: 1812 article-title: The role of mobile health technologies in stratifying patients for AIT and its cessation: the ARIA‐EAACI perspective publication-title: J Allergy Clin Immunol Pract – volume: 77 start-page: 1263 issue: 4 year: 2022 end-page: 1273 article-title: Coordinated IgG2 and IgE responses as a marker of allergen immunotherapy efficacy publication-title: Allergy – volume: 73 start-page: 1775 issue: 9 year: 2018 end-page: 1783 article-title: Clinical trials in allergen immunotherapy: current concepts and future needs publication-title: Allergy – volume: 70 start-page: 261 issue: 4 year: 1982 end-page: 271 article-title: Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six‐year prospective study publication-title: J Allergy Clin Immunol – volume: 77 start-page: 2688 issue: 9 year: 2022 end-page: 2698 article-title: Cost‐effectiveness analysis of house dust mite allergen immunotherapy in children with allergic asthma publication-title: Allergy – volume: 134 start-page: 568 issue: 3 year: 2014 end-page: 575.e7 article-title: Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double‐blind, placebo‐controlled trial publication-title: J Allergy Clin Immunol – volume: 22 start-page: 545 issue: 6 year: 2019 end-page: 553 article-title: Cost‐effectiveness analyses using real‐world data: an overview of the literature publication-title: J Med Econ – volume: 168 start-page: 213 issue: 3 year: 2015 end-page: 217 article-title: Cost‐effectiveness of immunotherapy in the treatment of seasonal allergic rhinitis: identifying product‐specific parameters of relevance for health care decision‐makers and clinicians publication-title: Int Arch Allergy Immunol – volume: 377 start-page: 62 issue: 1 year: 2017 end-page: 70 article-title: Master protocols to study multiple therapies, multiple diseases, or both publication-title: N Engl J Med – volume: 17 start-page: vi issue: 27 year: 2013 article-title: A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis publication-title: Health Technol Assess – volume: 131 start-page: 1288 issue: 5 year: 2013 end-page: 1296.e3 article-title: Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European academy of allergy and clinical immunology/PRACTALL consensus report publication-title: J Allergy Clin Immunol – volume: 141 start-page: 529 issue: 2 year: 2018 end-page: 538.e13 article-title: Results from the 5‐year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy publication-title: J Allergy Clin Immunol – volume: 10 year: 2020 article-title: Heterogeneous multi‐layered network model for omics data integration and analysis publication-title: Front Genet – volume: 12 year: 2021 article-title: Achieving precision medicine in allergic disease: progress and challenges publication-title: Front Immunol – year: 1987 – volume: 76 start-page: 2809 issue: 9 year: 2021 end-page: 2826 article-title: Immune changes beyond Th2 pathways during rapid multifood immunotherapy enabled with omalizumab publication-title: Allergy – volume: 131 start-page: 1204 year: 2013 end-page: 1212 article-title: IgG4 production is confined to human IL‐10‐producing regulatory B cells that suppress antigen‐specific immune responses publication-title: J Allergy Clin Immunol – volume: 73 start-page: 739 issue: 4 year: 2018 end-page: 743 article-title: EAACI guidelines on allergen immunotherapy: executive statement publication-title: Allergy – year: 2016 – volume: 23 start-page: 351 issue: 6 year: 2023 end-page: 362 article-title: Artificial intelligence: exploring the future of innovation in allergy immunology publication-title: Curr Allergy Asthma Rep – volume: 143 start-page: 1038 issue: 3 year: 2019 end-page: 1046 article-title: Predicting development of sustained unresponsiveness to milk oral immunotherapy using epitope‐specific antibody binding profiles publication-title: J Allergy Clin Immunol – volume: 4 start-page: 285 issue: 4 year: 1953 end-page: 288 article-title: Prophylactic inoculation against hay fever publication-title: Int Arch Allergy Appl Immunol – volume: 125 start-page: 383 issue: 2 year: 2010 end-page: 389 article-title: Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma publication-title: J Allergy Clin Immunol – volume: 150 start-page: 1279 issue: 6 year: 2022 end-page: 1288 article-title: Immunotherapy: state‐of‐the‐art review of therapies and theratypes publication-title: J Allergy Clin Immunol – volume: 72 start-page: 1597 issue: 11 year: 2017 end-page: 1631 article-title: Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta‐analysis publication-title: Allergy – start-page: 52 year: 2018 end-page: 60 – volume: 15 start-page: 906 issue: 5 year: 2012 end-page: 917 article-title: Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany publication-title: J Med Econ – volume: 13 start-page: 924 issue: 5 year: 2023 end-page: 941 article-title: Sublingual immunotherapy persistence and adherence in real‐world settings: a systematic review publication-title: Int Forum Allergy Rhinol – volume: 13 issue: 5 year: 2023 article-title: Mechanisms of allergen immunotherapy and potential biomarkers for clinical evaluation publication-title: J Pers Med – volume: 105 start-page: 9 issue: 1 year: 2002 end-page: 19 article-title: IgG4 breaking the rules publication-title: Immunology – volume: 26 start-page: 204 issue: 3 year: 2016 end-page: 207 article-title: The smartphone: a novel diagnostic tool in pollen allergy? publication-title: J Investig Allergol Clin Immunol – volume: 22 start-page: 387 issue: 6 year: 2022 end-page: 395 article-title: Strengthening the case for intralymphatic immunotherapy publication-title: Curr Opin Allergy Clin Immunol – volume: 207 start-page: 1161 issue: 9 year: 2023 end-page: 1170 article-title: Allergen immunotherapy enhances airway epithelial antiviral immunity in patients with allergic asthma (VITAL study): a double‐blind randomized controlled trial publication-title: Am J Respir Crit Care Med – volume: 15 start-page: 27 issue: 1_suppl year: 2018 end-page: 32 article-title: The evolution of clinical trials: can we address the challenges of the future? publication-title: Clin Trials – volume: 77 start-page: 2698 year: 2022 article-title: Cost‐effectiveness analysis of house dust mite allergen immunotherapy in children with allergic asthma [published online ahead of print, 2022 Apr 22] publication-title: Allergy – volume: 23 start-page: 335 issue: 1 year: 2023 article-title: Patient perspectives on data sharing regarding implementing and using artificial intelligence in general practice – a qualitative study publication-title: BMC Health Serv Res – volume: 76 start-page: 3589 issue: 12 year: 2021 end-page: 3612 article-title: Technical standards in allergen exposure chambers worldwide – an EAACI task force report publication-title: Allergy – volume: 149 year: 2022 article-title: Novel machine learning‐led discovery of adjuvant drug candidate for allergen immunotherapy using synthetic toll‐like receptor 2/6 agonist publication-title: J Allergy Clin Immunol – volume: 13 start-page: 2416 issue: 10 year: 2017 end-page: 2427 article-title: Adjuvants for allergy immunotherapeutics publication-title: Hum Vaccin Immunother – volume: 76 start-page: 3627 issue: 12 year: 2021 end-page: 3641 article-title: The role of allergen‐specific IgE, IgG and IgA in allergic disease publication-title: Allergy – volume: 75 start-page: 2685 issue: 10 year: 2020 end-page: 2686 article-title: The frequency of CD4+ CD25+ FoxP3+ CD127− cells in bet v 1 contiguous overlapping peptide immunotherapy as a putative marker of efficacy publication-title: Allergy – volume: 12 issue: 1 year: 2022 article-title: Multi‐omics profiling approach to asthma: an evolving paradigm publication-title: J Pers Med – volume: 143 start-page: 1131 issue: 3 year: 2019 end-page: 1142.e4 article-title: Role of IL‐35 in sublingual allergen immunotherapy publication-title: J Allergy Clin Immunol – volume: 180 start-page: 4514 issue: 7 year: 2008 end-page: 4522 article-title: Assessment of bet v 1‐specific CD4+ T cell responses in allergic and nonallergic individuals using MHC class II peptide tetramers publication-title: J Immunol – volume: 134 start-page: 671 issue: 3 year: 2014 end-page: 678.e4 article-title: Enhanced innate type 2 immune response in peripheral blood from patients with asthma publication-title: J Allergy Clin Immunol – volume: 205 start-page: 2887 issue: 12 year: 2008 end-page: 2898 article-title: In vivo switch to IL‐10‐secreting T regulatory cells in high dose allergen exposure publication-title: J Exp Med – volume: 111 start-page: 1255 issue: 6 year: 2003 end-page: 1261 article-title: Induction of IL‐10+CD4+CD25+ T cells by grass pollen immunotherapy publication-title: J Allergy Clin Immunol – volume: 278 start-page: 219 issue: 1 year: 2017 end-page: 236 article-title: Mechanisms of immune regulation in allergic diseases: the role of regulatory T and B cells publication-title: Immunol Rev – volume: 10 issue: 3 year: 2019 article-title: Challenges in the integration of omics and non‐omics data publication-title: Genes (Basel) – volume: 76 start-page: 3642 issue: 12 year: 2021 end-page: 3658 article-title: Molecular allergology and its impact in specific allergy diagnosis and therapy publication-title: Allergy – volume: 74 start-page: 2087 issue: 11 year: 2019 end-page: 2102 article-title: 2019 ARIA Care pathways for allergen immunotherapy publication-title: Allergy – volume: 73 start-page: 673 issue: 3 year: 2018 end-page: 682 article-title: Italian pediatric allergy network (I‐PAN). Diagnostic relevance of IgE sensitization profiles to eight recombinant Phleum pratense molecules publication-title: Allergy – volume: 76 start-page: 3390 issue: 11 year: 2021 end-page: 3407 article-title: Advances and highlights in asthma in 2021 publication-title: Allergy – volume: 10 year: 2021 article-title: Unsupervised machine learning reveals key immune cell subsets in COVID‐19, rhinovirus infection, and cancer therapy publication-title: Elife – volume: 71 start-page: 490 issue: 4 year: 2022 end-page: 497 article-title: Efficacy of a house dust mite sublingual immunotherapy tablet as add‐on dupilumab in asthma with rhinitis publication-title: Allergol Int – volume: 39 year: 2007 article-title: Pharmacoeconomics of subcutaneous allergen immunotherapy publication-title: Eur Ann Allergy Clin Immunol – volume: 5 start-page: 28 year: 2015 article-title: Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1‐FV in a randomized controlled trial publication-title: Clin Transl Allergy – volume: 11 issue: 9 year: 2021 article-title: Metabolomics reveals process of allergic rhinitis patients with single‐ and double‐species mite subcutaneous immunotherapy publication-title: Metabolites – volume: 28 start-page: 73 year: 2019 end-page: 81 article-title: Introduction to artificial intelligence in medicine publication-title: Minim Invasive Ther Allied Technol – volume: 317 start-page: 1554 issue: 5844 year: 2007 end-page: 1557 article-title: Anti‐inflammatory activity of human IgG4 antibodies by dynamic fab arm exchange publication-title: Science – volume: 15 start-page: 5 year: 2017 article-title: Pharmacoeconomics of sublingual immunotherapy with the 5‐grass pollen tablets for seasonal allergic rhinitis publication-title: Clin Mol Allergy – volume: 77 start-page: 454 issue: 2 year: 2022 end-page: 468 article-title: One hundred and ten years of allergen immunotherapy: A journey from empiric observation to evidence publication-title: Allergy – volume: 19 start-page: 1229 issue: 9 year: 2018 end-page: 1242 article-title: Impact of increasing treatment rates on cost‐effectiveness of subcutaneous immunotherapy (SCIT) in respiratory allergy: a decision analytic modelling approach publication-title: Eur J Health Econ – volume: 5 start-page: 89 issue: 1 year: 1987 end-page: 106 article-title: Standardized extracts modified allergens‐allergoids publication-title: Clin Rev Allergy – volume: 210 year: 2023 article-title: Allergen immunotherapy for allergic asthma: the future seems bright publication-title: Respir Med – volume: 178 year: 2021 article-title: Geographical and socioeconomic differences in compliance with and access to allergen immunotherapy in Denmark: a nationwide registry‐based study – 1998–2016 publication-title: Respir Med – volume: 21 start-page: 374 issue: 4 year: 2018 end-page: 381 article-title: Cost‐effectiveness of grass pollen subcutaneous immunotherapy (SCIT) compared to sublingual immunotherapy (SLIT) and symptomatic treatment in Austria, Spain, and Switzerland publication-title: J Med Econ – volume: 149 start-page: 1018 issue: 3 year: 2022 end-page: 1030.e11 article-title: A novel functional mast cell assay for the detection of allergies publication-title: J Allergy Clin Immunol – volume: 341 start-page: 468 issue: 7 year: 1999 end-page: 475 article-title: Long‐term clinical efficacy of grass‐pollen immunotherapy publication-title: N Engl J Med – volume: 121 start-page: 1467 issue: 6 year: 2008 end-page: 1472.e1 article-title: Grass pollen immunotherapy induces Foxp3‐expressing CD4+ CD25+ cells in the nasal mucosa publication-title: J Allergy Clin Immunol – volume: 74 start-page: 855 issue: 5 year: 2019 end-page: 873 article-title: EAACI guidelines on allergen immunotherapy: house dust mite‐driven allergic asthma publication-title: Allergy – volume: 109 start-page: 251 issue: 2 year: 2002 end-page: 256 article-title: Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT‐study) publication-title: J Allergy Clin Immunol – volume: 76 start-page: 2663 issue: 9 year: 2021 end-page: 2672 article-title: Allergen immunotherapy: the growing role of observational and randomized trial “real‐world evidence” publication-title: Allergy – volume: 78 start-page: 1113 issue: 4 year: 2023 end-page: 1116 article-title: Patient‐reported outcome measures in birch pollen allergic patients treated with sublingual immunotherapy reflect real life publication-title: Allergy – volume: 19 start-page: 402 issue: 4 year: 2019 end-page: 414 article-title: Recombinant allergens for immunotherapy: state of the art publication-title: Curr Opin Allergy Clin Immunol – volume: 13 issue: 12 year: 2020 article-title: Effectiveness and safety of a glutaraldehyde‐modified, L‐tyrosine‐adsorbed and monophosphoryl lipid A‐adjuvanted allergen immunotherapy in patients with allergic asthma sensitized to olive pollen: a retrospective, controlled real‐world study publication-title: World Allergy Organ J – volume: 73 start-page: 765 issue: 4 year: 2018 end-page: 798 article-title: EAACI guidelines on allergen immunotherapy: allergic rhinoconjunctivitis publication-title: Allergy – volume: 149 start-page: 833 issue: 3 year: 2022 end-page: 843 article-title: Which patients with asthma are most likely to benefit from allergen immunotherapy? publication-title: J Allergy Clin Immunol – volume: 379 start-page: 1991 issue: 21 year: 2018 end-page: 2001 article-title: AR101 oral immunotherapy for Peanut allergy publication-title: N Engl J Med – volume: 12 start-page: 850 issue: 5 year: 2021 end-page: 862 article-title: Efficient, automated and robust pollen analysis using deep learning publication-title: Methods Ecol Evol – volume: 78 start-page: 822 issue: 3 year: 2023 end-page: 835 article-title: RNA sequencing of single allergen‐specific memory B cells after grass pollen immunotherapy: two unique cell fates and CD29 as a biomarker for treatment effect publication-title: Allergy – volume: 27 start-page: 68 issue: 1 year: 1997 end-page: 74 article-title: Measurement of IgE antibodies against purified grass pollen allergens (lol p 1, 2, 3 and 5) during immunotherapy publication-title: Clin Exp Allergy – volume: 77 start-page: 3084 issue: 10 year: 2022 end-page: 3095 article-title: Molecular reactivity profiling upon immunotherapy with a 300 IR sublingual house dust mite tablet reveals marked humoral changes towards major allergens publication-title: Allergy – volume: 10 issue: 10 year: 2022 article-title: Identifying modifiable predictors of COVID‐19 vaccine side effects: a machine learning approach publication-title: Vaccines (Basel) – volume: 74 start-page: 2157 issue: 11 year: 2019 end-page: 2166 article-title: Modulation of CRTh2 expression on allergen‐specific T cells following peptide immunotherapy publication-title: Allergy – volume: 75 start-page: 450 issue: 2 year: 2020 end-page: 453 article-title: Allergen immunotherapy with the hypoallergenic B‐cell epitope‐based vaccine BM32 modifies IL‐10‐ and IL‐5‐secreting T cells publication-title: Allergy – volume: 60 issue: 5 year: 2022 article-title: Allergen immunotherapy effectively reduces the risk of exacerbations and lower respiratory tract infections in both seasonal and perennial allergic asthma: a nationwide epidemiological study publication-title: Eur Respir J – volume: 149 start-page: 1691 issue: 5 year: 2022 end-page: 1701.e9 article-title: CD38+ B cells affect immunotherapy for allergic rhinitis publication-title: J Allergy Clin Immunol – volume: 134 start-page: 741 issue: 3 year: 2014 end-page: 744.e5 article-title: Early improvement in basophil sensitivity predicts symptom relief with grass pollen immunotherapy publication-title: J Allergy Clin Immunol – ident: e_1_2_16_32_1 doi: 10.1172/JCI118963 – ident: e_1_2_16_18_1 – ident: e_1_2_16_82_1 doi: 10.1111/cea.12386 – ident: e_1_2_16_162_1 doi: 10.1185/030079906X112552 – ident: e_1_2_16_201_1 doi: 10.1002/jcp.29941 – ident: e_1_2_16_88_1 doi: 10.1111/pai.13829 – ident: e_1_2_16_72_1 doi: 10.1016/j.jaip.2020.11.046 – ident: e_1_2_16_207_1 doi: 10.1016/j.jaip.2022.11.036 – ident: e_1_2_16_42_1 doi: 10.1111/j.1398-9995.2010.02430.x – ident: e_1_2_16_161_1 doi: 10.1016/j.jaci.2015.12.1300 – ident: e_1_2_16_177_1 doi: 10.1111/all.14723 – ident: e_1_2_16_86_1 doi: 10.1016/j.jaci.2020.03.029 – ident: e_1_2_16_216_1 doi: 10.1001/jama.2016.3964 – ident: e_1_2_16_58_1 doi: 10.1111/all.15089 – ident: e_1_2_16_222_1 doi: 10.1111/all.13598 – ident: e_1_2_16_109_1 doi: 10.1016/j.jaci.2017.06.014 – ident: e_1_2_16_205_1 doi: 10.1111/all.15217 – ident: e_1_2_16_128_1 doi: 10.1097/ACI.0000000000000808 – ident: e_1_2_16_56_1 doi: 10.1111/all.14639 – ident: e_1_2_16_101_1 doi: 10.1111/all.14773 – ident: e_1_2_16_123_1 doi: 10.1111/all.13805 – ident: e_1_2_16_40_1 doi: 10.1016/j.jaci.2013.01.014 – ident: e_1_2_16_187_1 doi: 10.1016/j.ebiom.2019.11.006 – ident: e_1_2_16_149_1 doi: 10.1371/journal.pone.0283141 – ident: e_1_2_16_219_1 doi: 10.1111/all.13749 – ident: e_1_2_16_65_1 doi: 10.1016/j.jaci.2022.01.012 – ident: e_1_2_16_180_1 doi: 10.1007/s40521-013-0006-5 – volume: 39 year: 2007 ident: e_1_2_16_160_1 article-title: Pharmacoeconomics of subcutaneous allergen immunotherapy publication-title: Eur Ann Allergy Clin Immunol – ident: e_1_2_16_75_1 doi: 10.1186/s13052-020-00870-z – ident: e_1_2_16_124_1 doi: 10.1111/all.15550 – ident: e_1_2_16_214_1 doi: 10.1016/j.jaci.2022.10.007 – ident: e_1_2_16_9_1 doi: 10.1016/j.jaip.2021.11.017 – ident: e_1_2_16_10_1 doi: 10.1016/j.jaci.2012.02.026 – ident: e_1_2_16_131_1 doi: 10.1111/all.15485 – ident: e_1_2_16_164_1 doi: 10.1080/13696998.2019.1588737 – ident: e_1_2_16_11_1 doi: 10.1097/ACI.0000000000000857 – ident: e_1_2_16_116_1 – ident: e_1_2_16_69_1 doi: 10.3390/metabo11090613 – ident: e_1_2_16_144_1 doi: 10.1002/met.1905 – ident: e_1_2_16_111_1 doi: 10.1002/alr.23086 – ident: e_1_2_16_95_1 doi: 10.1056/NEJMra1510062 – ident: e_1_2_16_135_1 doi: 10.3389/fimmu.2021.720746 – ident: e_1_2_16_195_1 doi: 10.1016/j.waojou.2020.100487 – ident: e_1_2_16_24_1 doi: 10.1016/j.jaci.2013.01.049 – ident: e_1_2_16_134_1 doi: 10.1039/c7mo00051k – ident: e_1_2_16_212_1 doi: 10.1016/j.jaci.2022.08.029 – ident: e_1_2_16_191_1 doi: 10.1038/s41467-018-03636-8 – ident: e_1_2_16_104_1 doi: 10.1111/pai.13517 – ident: e_1_2_16_23_1 doi: 10.1067/mai.2002.121317 – ident: e_1_2_16_6_1 doi: 10.1111/all.13317 – ident: e_1_2_16_139_1 doi: 10.1080/13645706.2019.1575882 – ident: e_1_2_16_183_1 doi: 10.1159/000233058 – ident: e_1_2_16_34_1 doi: 10.1067/mai.2003.1570 – ident: e_1_2_16_206_1 doi: 10.1111/all.14833 – ident: e_1_2_16_46_1 doi: 10.1111/all.14776 – ident: e_1_2_16_156_1 doi: 10.1111/all.13254 – ident: e_1_2_16_203_1 doi: 10.2147/JAA.S318892 – ident: e_1_2_16_169_1 doi: 10.1186/s13223-019-0344-3 – ident: e_1_2_16_83_1 doi: 10.1111/all.14969 – ident: e_1_2_16_193_1 doi: 10.1016/j.jaci.2021.06.012 – ident: e_1_2_16_25_1 doi: 10.1016/j.jaci.2013.03.019 – ident: e_1_2_16_171_1 doi: 10.1186/s12948-017-0058-3 – ident: e_1_2_16_209_1 doi: 10.15586/aei.v50i2.469 – ident: e_1_2_16_114_1 doi: 10.1007/s40629-021-00183-5 – ident: e_1_2_16_8_1 doi: 10.1056/NEJMoa1812856 – ident: e_1_2_16_80_1 doi: 10.1111/cea.13867 – ident: e_1_2_16_96_1 doi: 10.1002/sim.6472 – ident: e_1_2_16_112_1 doi: 10.1002/alr.23078 – ident: e_1_2_16_50_1 doi: 10.1016/0091-6749(82)90062-8 – ident: e_1_2_16_146_1 doi: 10.1038/s41746-021-00423-6 – ident: e_1_2_16_228_1 – ident: e_1_2_16_68_1 doi: 10.1111/pai.13569 – ident: e_1_2_16_225_1 doi: 10.1164/rccm.202209-1708OC – ident: e_1_2_16_31_1 doi: 10.1002/eji.200322919 – ident: e_1_2_16_76_1 doi: 10.1007/s15007-021-4914-6 – ident: e_1_2_16_63_1 doi: 10.1016/j.immuni.2020.12.013 – ident: e_1_2_16_26_1 doi: 10.1111/all.15036 – ident: e_1_2_16_77_1 doi: 10.18176/jiaci.0060 – ident: e_1_2_16_14_1 doi: 10.1016/j.jaci.2022.01.011 – volume-title: European Medicines Agency: Committee on Medicinal Products for Human Use Guideline on the Clinical Development of Products for Specific Immunotherapy for the Treatment of Allergic Diseases. CHMP/EWP/18504/2006 year: 2008 ident: e_1_2_16_154_1 – ident: e_1_2_16_19_1 doi: 10.1016/j.coi.2006.06.003 – ident: e_1_2_16_211_1 doi: 10.1016/j.jaip.2018.09.015 – ident: e_1_2_16_174_1 doi: 10.1007/s10198-018-0970-6 – ident: e_1_2_16_142_1 doi: 10.3389/fgene.2019.01381 – ident: e_1_2_16_190_1 doi: 10.1186/2045-7022-3-17 – ident: e_1_2_16_30_1 doi: 10.1172/JCI2250 – ident: e_1_2_16_159_1 doi: 10.1080/14737167.2020.1819793 – ident: e_1_2_16_53_1 doi: 10.1046/j.0019-2805.2001.01341.x – ident: e_1_2_16_74_1 doi: 10.1016/j.jaip.2021.02.035 – ident: e_1_2_16_79_1 doi: 10.1186/s13601-020-00342-x – ident: e_1_2_16_173_1 doi: 10.3111/13696998.2012.688904 – ident: e_1_2_16_107_1 doi: 10.1097/ACI.0000000000000757 – ident: e_1_2_16_140_1 doi: 10.1111/all.15778 – ident: e_1_2_16_151_1 doi: 10.1016/j.jaci.2021.12.260 – ident: e_1_2_16_122_1 doi: 10.1111/all.15199 – ident: e_1_2_16_170_1 doi: 10.1111/all.15321 – ident: e_1_2_16_184_1 doi: 10.1186/s13601-015-0071-x – ident: e_1_2_16_52_1 doi: 10.1111/all.15107 – ident: e_1_2_16_145_1 doi: 10.3390/vaccines10101747 – ident: e_1_2_16_28_1 doi: 10.1016/s0091-6749(98)70079-x – ident: e_1_2_16_137_1 doi: 10.3390/jpm12010066 – ident: e_1_2_16_198_1 doi: 10.1007/s11882-018-0827-1 – ident: e_1_2_16_97_1 doi: 10.1111/all.15117 – ident: e_1_2_16_35_1 doi: 10.1084/jem.20080193 – ident: e_1_2_16_44_1 doi: 10.1016/j.jaci.2014.09.049 – ident: e_1_2_16_172_1 doi: 10.2147/CEOR.S44079 – ident: e_1_2_16_60_1 doi: 10.1111/all.15408 – ident: e_1_2_16_121_1 doi: 10.1111/all.12383 – ident: e_1_2_16_15_1 doi: 10.1016/j.pharmthera.2022.108115 – ident: e_1_2_16_181_1 doi: 10.1097/ACI.0000000000000536 – ident: e_1_2_16_78_1 doi: 10.1111/all.15499 – ident: e_1_2_16_120_1 doi: 10.1111/all.13355 – ident: e_1_2_16_153_1 – ident: e_1_2_16_227_1 doi: 10.1111/all.14575 – ident: e_1_2_16_7_1 doi: 10.1002/clt2.12268 – ident: e_1_2_16_5_1 doi: 10.1111/all.13201 – ident: e_1_2_16_59_1 doi: 10.7554/eLife.64653 – ident: e_1_2_16_47_1 doi: 10.1016/j.jaci.2014.07.029 – ident: e_1_2_16_43_1 doi: 10.1016/j.jaci.2014.04.029 – ident: e_1_2_16_138_1 doi: 10.1186/s12913-023-09324-8 – ident: e_1_2_16_3_1 doi: 10.1111/all.15023 – ident: e_1_2_16_70_1 doi: 10.1111/all.14342 – ident: e_1_2_16_176_1 doi: 10.1111/all.15321 – ident: e_1_2_16_189_1 doi: 10.1111/all.13867 – ident: e_1_2_16_155_1 doi: 10.1080/03007995.2017.1359517 – ident: e_1_2_16_188_1 doi: 10.1111/all.13996 – ident: e_1_2_16_199_1 doi: 10.1111/j.1365-2222.2008.03191.x – ident: e_1_2_16_119_1 doi: 10.1111/all.13429 – ident: e_1_2_16_49_1 doi: 10.1046/j.1365-2222.1997.d01-416.x – ident: e_1_2_16_36_1 doi: 10.1016/j.jaci.2008.03.013 – ident: e_1_2_16_179_1 – ident: e_1_2_16_117_1 – ident: e_1_2_16_48_1 doi: 10.1016/j.jaci.2018.12.1018 – ident: e_1_2_16_85_1 doi: 10.1016/j.jaci.2011.10.045 – volume-title: Methods for the Economic Evaluation of Health Care Programmes year: 1987 ident: e_1_2_16_166_1 – ident: e_1_2_16_92_1 doi: 10.1186/s13073-022-01102-1 – ident: e_1_2_16_210_1 doi: 10.1111/cea.12997 – ident: e_1_2_16_71_1 doi: 10.1016/j.jaci.2021.09.029 – start-page: 52 volume-title: Weißbuch Allergie in Deutschland. überarb. und erw. Aufl. München year: 2018 ident: e_1_2_16_157_1 – ident: e_1_2_16_167_1 doi: 10.3310/hta17270 – ident: e_1_2_16_37_1 doi: 10.1016/S0140-6736(04)15592-X – ident: e_1_2_16_152_1 doi: 10.1111/all.15667 – ident: e_1_2_16_29_1 doi: 10.1016/j.jaci.2009.02.030 – ident: e_1_2_16_208_1 doi: 10.1016/j.jaci.2009.11.022 – ident: e_1_2_16_57_1 doi: 10.1186/s12948-021-00150-z – ident: e_1_2_16_94_1 – ident: e_1_2_16_73_1 doi: 10.1111/all.13953 – ident: e_1_2_16_118_1 doi: 10.1111/all.13135 – ident: e_1_2_16_62_1 doi: 10.1016/j.jaci.2020.10.029 – ident: e_1_2_16_168_1 doi: 10.1159/000443272 – ident: e_1_2_16_204_1 doi: 10.1016/j.alit.2022.05.010 – ident: e_1_2_16_221_1 doi: 10.1016/j.jaci.2018.06.041 – ident: e_1_2_16_158_1 doi: 10.1007/s00103-011-1427-6 – ident: e_1_2_16_61_1 doi: 10.1111/all.14264 – ident: e_1_2_16_39_1 doi: 10.4049/jimmunol.180.7.4514 – ident: e_1_2_16_110_1 doi: 10.1016/j.lanepe.2021.100275 – ident: e_1_2_16_38_1 doi: 10.1371/journal.pone.0011028 – ident: e_1_2_16_16_1 doi: 10.3390/jpm13050845 – ident: e_1_2_16_220_1 doi: 10.1111/all.14908 – ident: e_1_2_16_217_1 doi: 10.1016/j.jaci.2014.03.019 – ident: e_1_2_16_223_1 doi: 10.2217/imt-2022-0215 – ident: e_1_2_16_51_1 doi: 10.1111/j.1398-9995.2008.01774.x – ident: e_1_2_16_102_1 doi: 10.12688/f1000research.13585.2 – ident: e_1_2_16_22_1 doi: 10.1111/all.14896 – ident: e_1_2_16_55_1 doi: 10.1016/j.jaci.2021.03.030 – ident: e_1_2_16_27_1 doi: 10.5415/apallergy.2022.12.e45 – ident: e_1_2_16_66_1 doi: 10.1016/j.jaci.2021.03.030 – ident: e_1_2_16_132_1 doi: 10.1111/all.14957 – ident: e_1_2_16_215_1 doi: 10.1111/imr.12555 – ident: e_1_2_16_127_1 – ident: e_1_2_16_196_1 doi: 10.1016/j.jaci.2017.02.044 – ident: e_1_2_16_175_1 doi: 10.1016/j.jaip.2014.01.010 – ident: e_1_2_16_12_1 doi: 10.1056/NEJMoa2212895 – ident: e_1_2_16_129_1 doi: 10.1016/j.jaci.2014.10.045 – ident: e_1_2_16_108_1 doi: 10.2500/aap.2020.41.200035 – ident: e_1_2_16_186_1 doi: 10.1016/j.jaci.2017.09.052 – ident: e_1_2_16_20_1 doi: 10.1056/NEJM199908123410702 – ident: e_1_2_16_13_1 doi: 10.1016/j.rmed.2023.107125 – ident: e_1_2_16_33_1 doi: 10.1038/nm1226 – ident: e_1_2_16_141_1 doi: 10.1007/s11882-023-01084-z – ident: e_1_2_16_130_1 doi: 10.1111/all.13133 – ident: e_1_2_16_90_1 doi: 10.1111/j.1398-9995.2007.01451.x – ident: e_1_2_16_84_1 doi: 10.1016/j.jaci.2014.01.042 – ident: e_1_2_16_103_1 doi: 10.1111/cea.13887 – ident: e_1_2_16_226_1 doi: 10.1183/13993003.00446-2022 – ident: e_1_2_16_136_1 doi: 10.3390/genes10030238 – ident: e_1_2_16_200_1 doi: 10.1097/ACI.0000000000000782 – ident: e_1_2_16_67_1 doi: 10.1016/j.jaci.2021.08.006 – ident: e_1_2_16_113_1 doi: 10.1080/13696998.2017.1419959 – ident: e_1_2_16_218_1 doi: 10.1111/all.15203 – ident: e_1_2_16_133_1 doi: 10.1111/all.15412 – ident: e_1_2_16_41_1 doi: 10.1016/j.jaci.2014.07.041 – ident: e_1_2_16_98_1 doi: 10.1177/1740774518755058 – ident: e_1_2_16_192_1 doi: 10.1016/j.jaci.2021.05.039 – ident: e_1_2_16_213_1 doi: 10.1111/all.15054 – ident: e_1_2_16_81_1 doi: 10.2196/16642 – ident: e_1_2_16_197_1 doi: 10.3389/fimmu.2021.590054 – ident: e_1_2_16_126_1 doi: 10.1111/all.14331 – ident: e_1_2_16_99_1 doi: 10.5414/ALX02343E – ident: e_1_2_16_143_1 doi: 10.1111/2041-210X.13575 – ident: e_1_2_16_148_1 doi: 10.1111/pai.13433 – ident: e_1_2_16_185_1 doi: 10.1111/all.14817 – ident: e_1_2_16_125_1 doi: 10.1007/s00105-017-3937-0 – ident: e_1_2_16_165_1 doi: 10.1080/1744666X.2021.1886079 – ident: e_1_2_16_4_1 doi: 10.1111/all.13420 – ident: e_1_2_16_91_1 doi: 10.1111/pai.13854 – ident: e_1_2_16_202_1 doi: 10.1111/all.15252 – ident: e_1_2_16_147_1 doi: 10.1016/j.jaci.2020.08.005 – ident: e_1_2_16_87_1 doi: 10.1111/all.15327 – ident: e_1_2_16_89_1 doi: 10.1111/all.13338 – ident: e_1_2_16_21_1 doi: 10.1111/all.14710 – ident: e_1_2_16_64_1 doi: 10.1111/all.15529 – ident: e_1_2_16_150_1 doi: 10.1016/j.jaci.2018.10.028 – ident: e_1_2_16_178_1 doi: 10.1159/000531332 – ident: e_1_2_16_2_1 doi: 10.1159/000228032 – ident: e_1_2_16_17_1 – ident: e_1_2_16_45_1 doi: 10.1016/j.jaci.2014.06.024 – ident: e_1_2_16_163_1 doi: 10.5414/ALX02331E – ident: e_1_2_16_105_1 doi: 10.1016/j.rmed.2021.106332 – ident: e_1_2_16_115_1 doi: 10.1111/all.14246 – ident: e_1_2_16_194_1 doi: 10.1080/21645515.2017.1348447 – ident: e_1_2_16_54_1 doi: 10.1126/science.1144603 – ident: e_1_2_16_106_1 doi: 10.1111/all.15506 – ident: e_1_2_16_224_1 doi: 10.2217/imt-2018-0087 – ident: e_1_2_16_93_1 – ident: e_1_2_16_182_1 doi: 10.1007/BF02802259 – ident: e_1_2_16_100_1 doi: 10.1016/j.jaci.2021.12.781 |
| SSID | ssj0007290 |
| Score | 2.579462 |
| SecondaryResourceType | review_article |
| Snippet | The importance of allergen immunotherapy (AIT) is multifaceted, encompassing both clinical and quality‐of‐life improvements and cost‐effectiveness in the long... The importance of allergen immunotherapy (AIT) is multifaceted, encompassing both clinical and quality-of-life improvements and cost-effectiveness in the long... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 823 |
| SubjectTerms | Adjuvants allergen immunotherapy (AIT) Allergens Artificial Intelligence B-lymphocytes Biomarkers Clinical trials compliance cost effectiveness Desensitization, Immunologic diagnostic techniques Drug therapy efficacy endpoint Humans hypersensitivity Hypersensitivity - diagnosis Hypersensitivity - therapy Immunoglobulin G Immunotherapy Leukocytes (eosinophilic) mast cells memory novel vaccines patients phenotype Phenotypes Placebos quality of life telemedicine trial design |
| Title | Hot topics in allergen immunotherapy, 2023: Current status and future perspective |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fall.15945 https://www.ncbi.nlm.nih.gov/pubmed/37984449 https://www.proquest.com/docview/3020340915 https://www.proquest.com/docview/2892271878 https://www.proquest.com/docview/3153565873 |
| Volume | 79 |
| WOSCitedRecordID | wos001104383600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library customDbUrl: eissn: 1398-9995 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0007290 issn: 0105-4538 databaseCode: WIN dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1398-9995 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0007290 issn: 0105-4538 databaseCode: DRFUL dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3da9swED-6doy99Gtrl36hlj3sYS62JEdW-1TahhbS0I2V5c1IsgSB4IQ6Gey_78lW3JWuUOiLsdEZ9HW6n3S63wF8dV1qC1vwyGgjI24KEWmWxpGVrKtc4vk-6qwlfTEYZMOhvF2C00UsTMMP0R64ec2o12uv4EpX_yi5Go-P0Rbz9B2sJAnLfN4Gym_bZViEAxYEEBFHtQ60Qv4aT_vrU2P0DGE-Bay1xemtvamu67AagCY5a2bGBizZchM-3ARX-if4cTWZkdlkOjIVGZXEp1TxcZhk5ANGQljW3-_E5z0_IYHFifjwo3lFVFmQhoyETB-DNT_DXe_y1_lVFPIrRMZvU3AF1kIgQMkK6WKHpj6WVlLvtzSOilgUTlipYyEz2U0dT7V11HjXbSG6hiWWbcFyOSntFyDGaZ46qWlhJEKSTJvYOUaVVSpVseYd-Lbo6NwE8nGfA2OcLzYh2My87qIOHLWi04Zx439Ce4vRyoPSVTnzXlXcryZYfNgWo7p4H4gq7WRe5dg8StEei-xlGYZWAHFuJlgHtpuZ0NaEYW9wziU2qB7wl6uYn_X79cvO60V34SMOa7gZtAfLs_u53Yf35s9sVN0f1PMbn2KYHcDKxc_eXR-_fl8PHgBZgP76 |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fSxwxEB7Uivpitf46a2ta-tAHV_Y22cum-CKinLgeFhR9WzbZBA6OvcO9E_rfd2Y3t620guDbQmYhyWQyXzKZbwC-uV5kC1uIwGijAmEKGWgeh4FVvJe7LvF91FVLUjkYJA8P6mYBTua5MA0_RHvhRpZR79dk4HQh_ZeV56PRMTpjES_CO4FAgwo33F8O2n1Y-hsWRBCBQLv2vEL0jqf99bk3-gdiPkestcu5eP-2zm7Auoea7LRZG5uwYMsPsHLtg-lb8LM_nrLpeDI0FRuWjIqqUCYmG1LKiE_M-nXEqPL5D-Z5nBglIM0qlpcFa-hI2ORPuuY23F2c3571A19hITB0UME9WEuJECUplAsdOvtQWRVR5NK4SIaycNIqHUqVqF7sRKytiwwFbwvZM7xr-Q4slePS7gEzTovYKR0VRiEoSbQJneNRbvM8zkMtOvB9PtOZ8fTjVAVjlM2PITjMrJ6iDnxtRScN58b_hA7m6sq82VUZp7gqnli72PylbUaDoShIXtrxrMpweFGEHlkmL8tw9AOIdBPJO7DbLIW2JxxnQwihcEC1xl_uYnaapvXH_utFD2G1f3udZunl4OojrKGK_TuhA1iaPs7sJ1g2T9Nh9fi5Xuy_ATYA_7s |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS-QwEB-8VcQX9fTU9eMuyj3cw1W6TbppxBfRWxR7ix4KvpXmCxaW7mJ3Bf97J222p6gg-FbIFJJMJvNLJvMbgJ-2GxltNAuUVCJgSvNA0jgMjKDd3HYc30dVtSTl_X5ydyeu5uB4lgtT80M0F27OMqr92hm4GWv7zMrz4fAQnTGLv8A8c0VkWjB_9q93mzY7Mfd3LIghAoaW7ZmF3Eue5ueX_ugVyHyJWSun01v5XHdXYdmDTXJSr46vMGeKNVj868Pp63B9PpqQyWg8UCUZFMSVVXG5mGTgkkZ8atbjb-Jqnx8Rz-REXArStCR5oUlNSELG_xM2v8Ft78_N6XngaywEyh1VcBeWnCNISbSwoUV3HwojIhe7VDbiIdeWGyFDLhLRjS2LpbGRcuFbzbuKdgzdgFYxKswWEGUli62QkVYCYUkiVWgtjXKT53EeStaGX7OZzpQnIHd1MIbZ7CCCw8yqKWrDQSM6rlk33hLanakr84ZXZtRFVvHM2sHm_aYZTcbFQfLCjKZlhsOLIvTJPHlfhqInQKybcNqGzXopND2hOBuMMYEDqjT-fhezkzStPrY_LvoDFq_Oell60b_cgSXUsH8otAutyf3U7MGCepgMyvvvfrU_AdNmAHM |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hot+topics+in+allergen+immunotherapy%2C+2023%3A+Current+status+and+future+perspective&rft.jtitle=Allergy+%28Copenhagen%29&rft.au=Zemelka%E2%80%90Wiacek%2C+Magdalena&rft.au=Agache%2C+Ioana&rft.au=Akdis%2C+Cezmi+A.&rft.au=Akdis%2C+M%C3%BCbeccel&rft.date=2024-04-01&rft.issn=0105-4538&rft.volume=79&rft.issue=4&rft.spage=823&rft.epage=842&rft_id=info:doi/10.1111%2Fall.15945&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0105-4538&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0105-4538&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0105-4538&client=summon |